WO2018014820A1 - 一种荧光染料及其制备方法和用途 - Google Patents

一种荧光染料及其制备方法和用途 Download PDF

Info

Publication number
WO2018014820A1
WO2018014820A1 PCT/CN2017/093270 CN2017093270W WO2018014820A1 WO 2018014820 A1 WO2018014820 A1 WO 2018014820A1 CN 2017093270 W CN2017093270 W CN 2017093270W WO 2018014820 A1 WO2018014820 A1 WO 2018014820A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
synthesis
alkyl group
ring
compound
Prior art date
Application number
PCT/CN2017/093270
Other languages
English (en)
French (fr)
Inventor
朱麟勇
杨弋
张大生
杜增民
鲍丙坤
林秋宁
李燕
陈显军
杨立朋
包春燕
Original Assignee
华东理工大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 华东理工大学 filed Critical 华东理工大学
Priority to EP17830454.9A priority Critical patent/EP3489323A4/en
Priority to JP2019502739A priority patent/JP7186448B2/ja
Priority to US16/318,762 priority patent/US11365203B2/en
Publication of WO2018014820A1 publication Critical patent/WO2018014820A1/zh

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09BORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/02Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain containing an odd number of >CH- or >C[alkyl]- groups
    • C09B23/04Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain containing an odd number of >CH- or >C[alkyl]- groups one >CH- group, e.g. cyanines, isocyanines, pseudocyanines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/60Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/78Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09BORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/0008Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain
    • C09B23/005Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain the substituent being a COOH and/or a functional derivative thereof
    • C09B23/0058Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain the substituent being a COOH and/or a functional derivative thereof the substituent being CN
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09BORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/0091Methine or polymethine dyes, e.g. cyanine dyes having only one heterocyclic ring at one end of the methine chain, e.g. hemicyamines, hemioxonol
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09BORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B57/00Other synthetic dyes of known constitution
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00Luminescent, e.g. electroluminescent, chemiluminescent materials
    • C09K11/06Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64Fluorescence; Phosphorescence
    • G01N21/6428Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531Production of immunochemical test materials
    • G01N33/532Production of labelled immunochemicals
    • G01N33/533Production of labelled immunochemicals with fluorescent label
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10Non-macromolecular compounds
    • C09K2211/1018Heterocyclic compounds
    • C09K2211/1025Heterocyclic compounds characterised by ligands
    • C09K2211/1029Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10Non-macromolecular compounds
    • C09K2211/1018Heterocyclic compounds
    • C09K2211/1025Heterocyclic compounds characterised by ligands
    • C09K2211/1029Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom
    • C09K2211/1033Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom with oxygen
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10Non-macromolecular compounds
    • C09K2211/1018Heterocyclic compounds
    • C09K2211/1025Heterocyclic compounds characterised by ligands
    • C09K2211/1029Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom
    • C09K2211/1037Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom with sulfur
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10Non-macromolecular compounds
    • C09K2211/1018Heterocyclic compounds
    • C09K2211/1025Heterocyclic compounds characterised by ligands
    • C09K2211/1044Heterocyclic compounds characterised by ligands containing two nitrogen atoms as heteroatoms
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10Non-macromolecular compounds
    • C09K2211/1018Heterocyclic compounds
    • C09K2211/1025Heterocyclic compounds characterised by ligands
    • C09K2211/1092Heterocyclic compounds characterised by ligands containing sulfur as the only heteroatom
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10Non-macromolecular compounds
    • C09K2211/1018Heterocyclic compounds
    • C09K2211/1025Heterocyclic compounds characterised by ligands
    • C09K2211/1096Heterocyclic compounds characterised by ligands containing other heteroatoms

Definitions

  • the invention relates to the technical field of fluorescent dyes, in particular to a long-wavelength-emitting viscosity-responsive fluorescent dye, a preparation method thereof and use thereof.
  • Fluorescence methods have recently been developed as an important means of testing microscopic viscosity. Compared to other methods, fluorescence detection is unique in its sensitivity, in situ, instant, and visual. The method effectively utilizes the sensitivity of the fluorescence intensity of some dye probes to the viscosity of the surrounding medium, and implements effective monitoring of the viscosity of the medium by the change of the fluorescence intensity.
  • such viscosity-responsive fluorescent probes are twisted to form a charge transfer state in the TICT molecule after photoexcitation, and the excited state energy is mainly emitted in a non-radiative form, however, when the viscosity When the responsive dye is in a slightly viscous or relatively rigid microenvironment, the distortion of such viscosity responsive dye molecules becomes difficult, and the molecular conformation is limited.
  • the excited state energy of the dye is mainly in the form of radiant luminescence, that is, in the form of fluorescence. Show it out. Therefore, the fluorescence intensity of the molecular rotor directly reflects the viscosity of the surrounding medium.
  • viscosity-responsive fluorescent probes are based on the restriction of molecular conformation to activate fluorescence.
  • Molecular rotors are also widely used in the design of fluorescence-activated fluorogenic probes.
  • a molecular rotor with a thiazole orange structure is a typical dyeing agent. After the dye enters the nucleus and binds to DNA, the molecular conformation is limited (equivalent to a sharp increase in viscosity), the fluorescence is illuminated, and the dye does not have any part of the cell. Fluorescence, achieving a no-wash, low background dyeing effect.
  • binding to an antibody protein can achieve a background-free labeling of cell surface proteins (SG Christopher. et. al. Nat. Biotechnol. 2008, 26, 235-240.); binding to an aptamer can effect labeling of DNA (JSPaige et.al.Science.2011, 333, 642-646.); as well as binding to amyloid to illuminate molecular rotor fluorescence to achieve Alzheimer's disease; additionally through ligands or inhibitors and protein tags Or the combination of enzymes, and the introduction of the molecular rotor into the lumen of the enzyme, can achieve the specific fluorescence activation label or enzyme identification, detection and quantification of the protein.
  • molecular rotor dyes that are sensitive and responsive to long-wavelength emission such as yellow or red or even near-infrared spectrums are very vacant.
  • thiazole orange and its analogues have been widely used, such dyes have a dominant cationic structure and are easily combined with negatively charged biomacromolecules such as DNA, which may cause false positives in viscosity increase or high background in imaging applications.
  • biomacromolecules such as DNA
  • a novel structure of fluorescent dye is provided which has a long wavelength emission capability.
  • a fluorescent dye is provided, the structure of which is as shown in the formula (I),
  • D- is X 0 O- or N(X 1 )(X 2 )-, X 0 , X 1 , X 2 are each independently selected from hydrogen, alkyl and modified alkyl, and X 1 , X 2 are optionally mutually a heterocyclic ring that is saturated or unsaturated;
  • the B ring is at least one selected from the group consisting of an aromatic ring or an aromatic heterocyclic ring;
  • each of the hydrogen atoms contained is optionally independently selected from a halogen atom, a nitro group, a hydrophilic group, an alkyl group, and a modification. Substituted with a substituent of an alkyl group, which are optionally linked to each other to form a saturated or unsaturated alicyclic or heteroalicyclic ring;
  • the structure of formula (I-2) is linked to X 1 and X 2 to form an aliphatic heterocyclic ring;
  • R 1 is selected from the group consisting of hydrogen, a halogen atom, a nitro group, an alkyl group, an aryl group, a heteroaryl group, a hydrophilic group or a modified alkyl group;
  • R 2 is selected from the group consisting of cyano, carboxyl, keto, ester, amide, phosphonic acid, phosphonate, sulfonate, sulfonate, sulfone, sulfoxide, aryl, heteroaryl, An alkyl group or a modified alkyl group;
  • R 3 is a cyano group
  • R a , R b are independently selected from the group consisting of hydrogen, alkyl and modified alkyl, and R a and R b are optionally bonded to each other to form an alicyclic or heteroalicyclic ring;
  • R c , R d are independently selected from the group consisting of hydrogen, a halogen atom, a nitro group, an alkyl group, an aryl group, a hydrophilic group, and a modified alkyl group;
  • Y 3 is -C(R e )(CN);
  • R e is selected from the group consisting of cyano, carboxyl, keto, ester, amide, phosphonic acid, phosphonate, sulfonate, sulfonate, sulfone, sulfoxide, aryl, heteroaryl, An alkyl group or a modified alkyl group;
  • R 2 or R e is aryl or heteroaryl
  • the hydrogen atom on the ring is optionally independently substituted with a substituent selected from a halogen atom, a nitro group, a hydrophilic group, an alkyl group or a modified alkyl group. Substituting; optionally, the substituents are linked to each other to form a saturated or unsaturated alicyclic or heteroalicyclic ring;
  • the alkyl group is a saturated aliphatic straight or branched alkyl group having 1 to 10 carbon atoms;
  • the modified alkyl group has 1 to 50 carbon atoms, and the carbon-carbon single bond thereof is optionally independently substituted by a carbon-carbon double bond or a carbon-carbon triple bond;
  • the alicyclic ring is a 4 to 10 membered monocyclic or polycyclic alicyclic ring
  • the heteroalicyclic ring is a 4- to 10-membered monocyclic or polycyclic heterocyclic ring containing at least one hetero atom selected from N, O, S or Si, and when the heteroalicyclic ring contains an S atom, It is optionally -SO- or -SO 2 -; the heterocyclic heterocyclic ring is optionally substituted by a halogen atom, a nitro group, an alkyl group, an aryl group, a hydrophilic group and a modified alkyl group;
  • the aryl or aromatic ring is a 5- to 10-membered monocyclic or fused bicyclic ring
  • the heteroaryl or aromatic heterocyclic ring is a 5- to 10-membered monocyclic or fused bicyclic ring containing at least one hetero atom selected from N, O, S or Si;
  • the halogen atoms are each independently selected from the group consisting of F, Cl, Br, and I;
  • the hydrophilic group is a hydroxyl group, a sulfonic acid group, a sulfuric acid group, a phosphoric acid group, a primary amino group, a secondary amino group or a tertiary amino group and a substituent thereof;
  • the monocyclic cyclocyclic hydrocarbon group is a 4- to 7-membered cycloalkylene group
  • the bicyclic subcyclic hydrocarbon group is a 5- to 7-membered bicyclic ring-opened hydrocarbon group
  • the bridged heterocyclic ring is a 5- to 20-membered bridged heterocyclic ring containing at least one hetero atom selected from N, O, or S on the ring.
  • the heterocyclic ring is selected from the group consisting of azetidine, pyrrolidine, piperidine, tetrahydrofuran, tetrahydropyran, morpholine, thiomorpholine.
  • the heteroaromatic ring is selected from the group consisting of thiophene, furan and pyrrole.
  • the X 1 and X 2 are independently C 1-50 which are optionally substituted by one or more groups selected from a hydroxyl group, a cyano group, a halogen atom, a carboxyl group and a quaternary ammonium group. a linear or branched alkyl group; or a C 2-50 ether chain group having 1 to 10 oxygen atoms optionally substituted with one or more groups selected from a sulfonic acid group or a carboxyl group; or, N ( X 1 )(X 2 )- forms any group selected from the following formulas (I-1-1) to (I-1-4):
  • R k is hydrogen or C 1-10 alkyl.
  • two adjacent substituents in the structure of the formula (I-2) are linked to each other to form a saturated or unsaturated alicyclic or heterocyclic ring;
  • H on the CH in the ring B is substituted with a halogen atom, a nitro group, a hydrophilic group, an alkyl group or a modified alkyl group;
  • the ring B contains NH; alternatively, the H on the NH is substituted with an alkyl group or a modified alkyl group,
  • the structure of the formula (I-2) is selected from the structures of the following formulas (I-2-1) to (I-2-17):
  • the structure of the formula (I-2) is selected from the group consisting of formula (I-2-1), (I-2-3), (I-2-6), (I-2-7), (I-2). -9), (I-2-10), (I-2-11), (I-2-14), (I-2-15), (I-2-16) or (I-2-17 The structure in ).
  • the R 2 and R e are independently a group selected from the following structures, or a bicyclic or polycyclic fused aromatic ring or a fused aromatic heterocyclic ring formed by the following structures themselves or fused to each other: preferably a bicyclic or tricyclic fused aromatic ring or a fused aromatic heterocyclic ring;
  • H in the above structure of R 2 or R e is substituted by a halogen atom, a nitro group, a hydrophilic group, an alkyl group or a modified alkyl group; alternatively, R 2 or R e is selected From the NH-containing group in the above structure, optionally, H on the NH is substituted with an alkyl group or a modified alkyl group,
  • the R 2 and R e are independently a modified alkyl group: the modified alkyl group contains a keto group, an ester group or an amide group, and is bonded to the formula via a carbonyl group in a keto group, an ester group or an amide group ( I-3) or an alkenyl carbon of formula (I-3-a);
  • the structure of the formula (I-3) is one selected from the group consisting of the following formulae (I-3-1) to (I-3-18):
  • the structure of the formula (I-3) is selected from the group consisting of (I-3-1), (I-3-2), (I-3-4), (I-3-5), (I) -3-7), (I-3-9), (I-3-11), (I-3-12), (I-3-13), (I-3-16), (I-3 One of -17) or (I-3-18).
  • the fluorescent dye described above, wherein the fluorescent dye is selected from the group consisting of:
  • a process for the preparation of a fluorescent dye as described above which comprises the step of an aldol condensation reaction of a compound of formula (II) with a compound of formula (III).
  • a fluorescent dye as described above for viscosity testing protein fluorescent labeling, nucleic acid fluorescent labeling, protein quantification or detection, or nucleic acid quantification or detection.
  • a fluorescence activated lighting type probe comprising the above fluorescent dye.
  • a fluorescently activated light-emitting probe as described above for protein fluorescent labeling, nucleic acid fluorescent labeling, protein quantification or detection, or nucleic acid quantification or detection.
  • the resulting fluorescent dye has a long wavelength emission (>500 nm).
  • the fluorescence intensity of the obtained fluorescent dye increases as the environmental viscosity increases, and the logarithm of the logarithm of the fluorescence intensity and the viscosity of the solvent has a good linear relationship, and the relationship between the fluorescence intensity and the viscosity is in accordance with The Huffman equation, and has a higher slope, which is sensitive to viscosity and has a high activation factor.
  • the resulting fluorescent dye has good specificity for viscosity response and is insensitive to polarity changes.
  • a fluorescent dye can be used to determine the viscosity of a sample, such as a test suitable for microscopic viscosity.
  • the resulting fluorescent dye can specifically bind to a corresponding antibody, aptamer or amyloid, or a ligand or an inhibitor can be bound to a protein tag or enzyme to obtain a series of fluorescent activation sites.
  • Figure 1 is a graph showing the fluorescence emission intensity of molecular rotor 1 (1 ⁇ 10 -5 M) under different viscosity conditions;
  • Figure 3 is a graph showing the fluorescence emission intensity of molecular rotor 1 (1 ⁇ 10 -5 M) in methanol and dichloromethane;
  • Figure 4 is the fluorescence emission intensity of molecular rotor 2 (1 ⁇ 10 -5 M) under different viscosity conditions
  • Figure 5 is a linear relationship diagram between the viscosity condition of the molecular rotor 2 (1 ⁇ 10 -5 M) and the fluorescence intensity;
  • Figure 6 is a graph showing the fluorescence emission intensity of molecular rotor 2 (1 ⁇ 10 -5 M) in methanol and dichloromethane;
  • Figure 7 is a graph showing the fluorescence emission intensity of molecular rotor 3 (1 ⁇ 10 -5 M) under different viscosity conditions
  • Figure 8 is a linear relationship diagram between the viscosity condition of the molecular rotor 3 (1 ⁇ 10 -5 M) and the fluorescence intensity;
  • Figure 9 is a graph showing the fluorescence emission intensity of molecular rotor 3 (1 ⁇ 10 -5 M) in methanol and dichloromethane;
  • Figure 10 is a graph showing the fluorescence emission intensity of molecular rotor 22 (1 ⁇ 10 -5 M) under different viscosity conditions;
  • Figure 11 is a linear relationship between the viscosity condition of the molecular rotor 22 (1 ⁇ 10 -5 M) and the fluorescence intensity;
  • Figure 12 is a graph showing the fluorescence emission intensity of molecular rotor 22 (1 ⁇ 10 -5 M) in methanol and dichloromethane;
  • Figure 13 is a graph showing the fluorescence emission intensity of a molecular rotor 57 (1 ⁇ 10 -5 M) under different viscosity conditions;
  • Figure 14 is a linear relationship diagram between the viscosity condition of the molecular rotor 57 (1 ⁇ 10 -5 M) and the fluorescence intensity;
  • Figure 15 is a graph showing the fluorescence emission intensity of molecular rotor 57 (1 ⁇ 10 -5 M) in methanol and dichloromethane;
  • Figure 16 is a graph showing the fluorescence emission intensity of a molecular rotor 63 (1 ⁇ 10 -5 M) under different viscosity conditions;
  • Figure 17 is a linear relationship diagram between the viscosity condition of the molecular rotor 63 (1 ⁇ 10 -5 M) and the fluorescence intensity;
  • Figure 18 is a graph showing the fluorescence emission intensity of molecular rotor 63 (1 ⁇ 10 -5 M) in methanol and dichloromethane;
  • Figure 19 is a fluorescent image of probe 1 for intracellular carbonic anhydrase detection, wherein A is a cell that does not express carbonic anhydrase and B is a cell that expresses carbonic anhydrase.
  • the "molecular rotor" described in the following examples is an abbreviation for the long-wavelength-emitting viscosity-responsive fluorescent dye of the present invention.
  • the compound 18 (1.21 g, 5 mmol) was dissolved in anhydrous methanol, and then added with sodium methoxide (1.35 g, 25 mmol) of malononitrile (1.65 g, 25 ml) in a 60 ° C oil bath for 5 h, the reaction was completed, cooled to room temperature, and quenched with water.
  • the system is poured into 150 ml of water, diluted with hydrochloric acid to pH 2.0, extracted with dichloromethane, and the organic phase is combined, dried over anhydrous sodium sulfate, filtered and evaporated to remove Na 2 SO 4 , then evaporated to dryness The yield was 31%.
  • the crude product was dissolved in 30 ml of NMP, added with sodium sulfide nonahydrate (0.87 g, 3.63 mmol), heated under 190 ° C oil bath for 12 h under Ar protection, cooled to room temperature, added with 20 ml of saturated ammonium chloride solution, extracted three times with dichloromethane, and combined.
  • the organic phase Na 2 SO 4 the organic phase was dried, Na 2 SO 4, evaporated to dryness rotated by column to give a white solid 0.85 g, 49% yield was removed by filtration.
  • the fluorescent dyes (molecular rotors) prepared in Examples 1-68 were separately dissolved in dimethyl sulfoxide, and a mother liquor having a concentration of 1 ⁇ 10 -2 M was prepared, and each mother liquid was separately added to glycerin and methanol, and uniformly mixed. Each solution was prepared at a final concentration of 1 ⁇ 10 -5 M, and the fluorescence emission spectrum of each fluorescent dye was sequentially detected under the same conditions according to the different fluorescent dyes.
  • Table 1 indicating the fluorescent dye of the present invention. It has long wavelength emission fluorescence and is sensitive to viscosity changes.
  • Table 1 The emission wavelength of each molecular rotor and its ratio of fluorescence intensity in glycerol to methanol solution
  • the molecular rotors 1, 2, 3, 22, 57, 63 were added to a diethanol-glycerol mixed solution having a viscosity of 16.4 cp, 29.8 cp, 64.5 cp, 143.5 cp, 377.0 cp, and 946.0 cp to prepare a final concentration of 1 ⁇ 10.
  • -5 M solution, excitation at 480 nm, the fluorescence emission spectra under different viscosity conditions are shown in Figures 1, 4, 7, 10, 13, and 16.
  • the molecular rotor emission wavelengths are 555 nm, 590 nm, 610 nm, 570 nm, 559 nm, and 675 nm, respectively.
  • the molecular rotors 1, 2, 3, 22, 57, and 63 were separately added to dichloromethane and methanol to prepare a solution having a final concentration of 1 ⁇ 10 -5 M, and then excited at 480 nm, 480 nm, and 500 nm at 25 ° C, respectively.
  • the fluorescence intensity does not change much in the strong polar and strong non-polar solvents, indicating that the fluorescence intensity of the molecular rotor of the present invention is weak, and is insensitive to the polarity change reaction.
  • probe 1 The effect of probe 1 on the fluorescence monitoring of carbonic anhydrase was investigated by using Hela cells as an example.
  • HeLa cells highly expressing carbonic anhydrase and Hela-WT cells (Hela original cells) which were not expressed with carbonic anhydrase were planted in a 14 mm glass bottom 96-well cell culture plate and stabilized for 10 hours.
  • Probe 1 was added to the medium and brought to a concentration of 5 ⁇ M.
  • the cells were incubated for 2 hours in a 37 ° C carbon dioxide incubator, and the labeling cell fluorescence changes were detected using a Leica TPS-8 confocal microscope.
  • FIG. 19Aa show that after the addition of probe 1, the corresponding fluorescent signal was not detected in Hela-WT cells, indicating that the probe fluorescence was not affected by the intracellular environment; whereas the HeLa cells expressing carbonic anhydrase protein in Fig. 19Ba could A strong fluorescent signal was detected, and the fluorescence signal was enhanced by nearly 300-fold compared to Hela-WT cells. It is indicated that the probe of the present invention can specifically label intracellular carbonic anhydrase protein to achieve fluorescence-specific illumination, and at the same time, the probe fluorescence is not affected by the intracellular environment.
  • the fluorescent dye of the present invention is suitable for specific binding to a corresponding antibody, aptamer or amyloid, or by binding of a ligand or inhibitor to a protein tag or enzyme, and introducing the molecular rotor into
  • the means and methods of the enzyme lumen develop a series of fluorescence-activated illuminating probes for fluorescent labeling, quantification or monitoring of proteins, enzymes or nucleic acids.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

一种荧光染料及其制备方法和用途,所述荧光染料具有长波长发射的能力,对粘度响应敏感并且特异,可用于粘度测试,还可以作为荧光激活点亮型探针,用于蛋白、酶或核酸的荧光标记、定量或检测。

Description

一种荧光染料及其制备方法和用途 技术领域
本发明涉及荧光染料技术领域,具体涉及一种长波长发射的粘度响应性荧光染料及其制备方法和用途。
背景技术
荧光方法是最近发展起来测试微观粘度的一种重要手段。和其它方法相比,荧光检测具有灵敏、原位、即时、可视等独特优势。该方法有效利用了某些染料探针的荧光强度对周边介质粘度敏感的特点,通过荧光强度的变化,实施对介质的粘度的有效监测。当前,这类粘度响应性荧光探针,往往也被称作分子转子,它们在光激发后分子发生扭曲形成TICT分子内电荷转移态,激发态能量主要以非辐射的形式散发,然而,当粘度响应性染料处于粘度较大或较刚性的微环境时,此类粘度响应性染料分子扭曲变得困难,分子构象被限制,此时染料激发态能量主要以辐射发光的形式,即以荧光的形式表现出来。因此分子转子的荧光强度也就直接体现了周边介质的粘度大小。
重要的是,粘度响应性荧光探针除应用于粘度检测之外,基于限制分子构象激活荧光的特点,分子转子还被广泛应用于荧光激活点亮型探针(fluorogenic probe)的设计。例如,具有噻唑橙结构的分子转子是典型的染核试剂,该染料进入细胞核与DNA结合后,分子构象被限制(等同于粘度急剧增加),荧光被点亮,而染料在细胞其它部分没任何荧光,达到了免洗、低背景的染核效果。再如,与抗体蛋白结合可以实现细胞表面蛋白的无背景标记(S.G.Christopher.et.al.Nat.Biotechnol.2008,26,235-240.);与适配体结合可以实现DNA的标记点亮(J.S.Paige et.al.Science.2011,333,642-646.);还如与淀粉样蛋白结合点亮分子转子荧光可以实现艾滋海默病的研究;另外通过配体或抑制剂与蛋白标签或酶的结合,并将分子转子导入到酶的内腔,可以实现蛋白的特异性荧光激活标记或酶的识别、检测与定量。
然而,具有灵敏且响应特异的长波长发射比如黄色或红色甚至近红外谱系的粘度响应的分子转子染料非常空缺。虽然噻唑橙及其类似物已经应用非常广泛,但是该类染料具有显性阳离子结构,易与DNA等负电荷生物大分子结合,会造成粘度增高的假阳性,或者是影像应用中的高背景。另外,有少量报导的长波长粘度响应性荧光探针,大多存 在非特异的响应,特别是极性响应的特点。
发明内容
提供一种全新结构的荧光染料,所述荧光染料具有长波长发射能力。
为此,提供一种荧光染料,其结构如式(I)所示,
Figure PCTCN2017093270-appb-000001
其中:
D-为X0O-或N(X1)(X2)-,X0、X1、X2各自独立地选自氢、烷基和改性烷基,X1,X2任选相互连接为饱和或不饱和的脂杂环;
B环为选自芳香环或芳香杂环中的至少一种;
B环与噻吩环稠合所形成的下式(I-2)结构中,所含的各氢原子任选独立地被选自卤原子、硝基、亲水性基团、烷基和改性烷基的取代基取代,所述取代基任选地相互连接构成饱和或不饱和的脂环或脂杂环;
Figure PCTCN2017093270-appb-000002
任选地,所述式(I-2)结构与X1、X2相互连接形成脂杂环;
R1选自氢、卤原子、硝基、烷基、芳基、杂芳基、亲水性基团或改性烷基;
R2选自氰基、羧基、酮基、酯基、酰胺基、膦酸基、膦酸酯基、磺酸基、磺酸酯基、砜基、亚砜基、芳基、杂芳基、烷基或改性烷基;
R3为氰基;
式(I)中的下式(I-3)结构部分:
Figure PCTCN2017093270-appb-000003
任选形成下式(I-3-a)、(I-3-b)环状结构:
Figure PCTCN2017093270-appb-000004
其中,Ra、Rb独立地选自氢、烷基和改性烷基,Ra和Rb任选地相互连接形成脂环或脂杂环;
Rc、Rd独立地选自氢、卤原子、硝基、烷基、芳基、亲水性基团和改性烷基;
Y1选自-O-、-S-、-(S=O)-和-(NRi)-,其中Ri选自氢、烷基和改性烷基;
Y2选自=O、=S、=S=O和=NRi,其中Ri选自氢、烷基和改性烷基;
Y3选自=O、=S、=S=O和=NRi,其中Ri选自氢、烷基和改性烷基;
或者,Y3为-C(Re)(CN);
Re选自氰基、羧基、酮基、酯基、酰胺基、膦酸基、膦酸酯基、磺酸基、磺酸酯基、砜基、亚砜基、芳基、杂芳基、烷基或改性烷基;
当R2或Re为芳基或杂芳基时,环上的氢原子任选独立地被选自卤原子、硝基、亲水性基团、烷基或改性烷基中的取代基取代;任选地,所述取代基相互连接构成饱和或不饱和的脂环或脂杂环;
其中,
所述烷基为具有1~10个碳原子的饱和脂肪族直链或支链的烷基;
所述改性烷基为烷基的任意碳原子被选自卤原子、-O-、-OH、-CO-、-NO2、-CN、-S-、-SO2-、-(S=O)-、
Figure PCTCN2017093270-appb-000005
亚苯基、伯氨基、仲氨基、叔氨基、季铵盐基、饱和或不饱和的单环或双环亚环烃基、桥联脂杂环中的至少一种基团置换所得的基团,所述改性烷基具有1~50个碳原子,其碳碳单键任选独立地被碳碳双键或碳碳叁键置换;
所述脂环为4~10元单环或多环脂环;
所述脂杂环为环上含有选自N、O、S或Si中的至少一种杂原子的4~10元单环或多环脂杂环,所述脂杂环上含有S原子时,其任选为-SO-或-SO2-;所述脂杂环任选被卤原子、硝基、烷基、芳基、亲水性基团和改性烷基取代;
所述芳基或芳香环为5~10元单环或稠合双环;
所述杂芳基或芳香杂环为环上含有选自N、O、S或Si中的至少一种杂原子的5~10元单环或稠合双环;
所述卤原子各自独立地选自F、Cl、Br、I;
所述亲水性基团为羟基、磺酸基、硫酸基、磷酸基、伯氨基、仲氨基或叔氨基及其取代物;
所述单环亚环烃基为4~7元亚环烃基;
所述双环亚环烃基为5~7元双环亚环烃基;
所述桥联脂杂环为环上含有选自N、O、或S中的至少一种杂原子的5~20元桥联脂杂环。
可选地,上述的荧光染料,所述改性烷基为含有选自-OH、-O-、乙二醇单元、单糖单元、二糖单元、多糖单元、-O-CO-、-NH-CO-、-SO2-O-、-SO-、-SO2-NH-、-S-S-、-CH=CH-、-C≡C-、卤原子、氰基、硝基、磷酸酯基或膦酸酯基中至少一种基团的基团。
可选地,上述的荧光染料,所述脂杂环选自氮杂环丁烷、吡咯烷、哌啶、四氢呋喃、四氢吡喃、吗啉、硫代吗啉。
可选地,上述的荧光染料,所述杂芳环选自噻吩、呋喃、吡咯。
可选地,上述的荧光染料,所述X1、X2独立地为任选被1个或多个选自羟基、氰基、卤原子、羧基、季铵基团的基团取代的C1-50直链或支链烷基;或任选被1个或多个选自磺酸基、羧基的基团取代的含1-10个氧原子的C2-50醚链基团;或者,N(X1)(X2)-形成选自下式(I-1-1)~(I-1-4)的任一基团:
Figure PCTCN2017093270-appb-000006
其中,Rk为氢或者C1-10烷基。
可选地,上述的荧光染料,所述式(I-2)结构中两个相邻取代基相互连接构成饱和或不饱和的脂环或脂杂环;
可选地,B环中CH上的H被卤原子、硝基、亲水性基团、烷基或改性烷基取代;
可选地,B环中含有NH;可选地,所述NH上的H被烷基或改性烷基取代,
可选地,式(I-2)结构选自下式(I-2-1)~(I-2-17)中的结构:
Figure PCTCN2017093270-appb-000007
可选地,式(I-2)结构选自式(I-2-1)、(I-2-3)、(I-2-6)、(I-2-7)、(I-2-9)、(I-2-10)、(I-2-11)、(I-2-14)、(I-2-15)、(I-2-16)或(I-2-17)中的结构。
可选地,上述的荧光染料,其中,式(I-3-a)中Ra、Rb与所连接的碳原子一起形成:
Figure PCTCN2017093270-appb-000008
可选地,所述R2和Re独立地为选自以下结构的基团,或者,由以下结构自身或相互之间稠合形成的双环或多环稠芳香环或稠芳香杂环:优选为双环或三环稠芳香环或稠芳香杂环;
Figure PCTCN2017093270-appb-000009
可选的,R2或Re的上述结构中CH上的H被卤原子、硝基、亲水性基团、烷基或改 性烷基取代;可选地,R2或Re为选自上述结构中的含NH的基团,可选地,所述NH上的H被烷基或改性烷基取代,
或者,所述R2和Re独立地为改性烷基:所述改性烷基含有酮基、酯基或酰胺基,并且通过酮基、酯基或酰胺基中的羰基连接到式(I-3)或式(I-3-a)的烯基碳上;
可选地,所述式(I-3)结构为选自下式(I-3-1)~(I-3-18)中的一种:
Figure PCTCN2017093270-appb-000010
可选地,所述式(I-3)结构为选自(I-3-1)、(I-3-2)、(I-3-4)、(I-3-5)、(I-3-7)、(I-3-9)、(I-3-11)、(I-3-12)、(I-3-13)、(I-3-16)、(I-3-17)或(I-3-18)中的一种。
可选地,上述的荧光染料,其特征在于,所述荧光染料选自下式化合物:
Figure PCTCN2017093270-appb-000011
Figure PCTCN2017093270-appb-000012
Figure PCTCN2017093270-appb-000013
Figure PCTCN2017093270-appb-000014
另一个方面,还提供制备上述的荧光染料的方法,其特征在于,包括式(II)化合物与式(III)化合物发生羟醛缩合反应的步骤。
Figure PCTCN2017093270-appb-000015
另一个方面,还提供上述的荧光染料在粘度测试、蛋白荧光标记、核酸荧光标记、蛋白定量或检测、或者核酸定量或检测中的用途。
另一个方面,还提供一种荧光激活点亮型探针,其特征在于,包括上述荧光染料。
另一个方面,还提供上述的荧光激活点亮型探针在蛋白荧光标记、核酸荧光标记、蛋白定量或检测、或者核酸定量或检测中的用途。
根据一方面的具体实施方案,所得荧光染料具有长波长发射(>500nm)。根据另一方面的具体实施方案,所得荧光染料的荧光强度随环境粘度的增大而增强,荧光强度的对数和溶剂粘度的对数关系具有很好的线性关系,荧光强度与粘度的关系符合霍夫曼方程,并且具有较高斜率,其对粘度反应灵敏,激活倍数高。根据另一方面的具体实施方案,所得荧光染料对粘度响应具有良好的特异性,对极性变化反应不灵敏。
根据一方面的具体实施方案,荧光染料可用于测定样品的粘度,例如适用于微观粘度的测试。根据另一方面的具体实施方案,所得荧光染料可与对应的抗体、适配体或淀粉样蛋白等特异性结合,或者通过配体或抑制剂与蛋白标签或酶键合,获得系列荧光激活点亮型探针,用于蛋白、酶或核酸的荧光标记、定量或监测。
附图说明
图1为分子转子1(1×10-5M)在不同粘度条件下荧光发射强度图;
图2为分子转子1(1×10-5M)粘度条件与荧光强度的线性关系图;
图3为分子转子1(1×10-5M)在甲醇与二氯甲烷中荧光发射强度图;
图4为分子转子2(1×10-5M)在不同粘度条件下荧光发射强度;
图5为分子转子2(1×10-5M)粘度条件与荧光强度的线性关系图;
图6为分子转子2(1×10-5M)在甲醇与二氯甲烷中荧光发射强度图;
图7为分子转子3(1×10-5M)在不同粘度条件下荧光发射强度图;
图8为分子转子3(1×10-5M)粘度条件与荧光强度的线性关系图;
图9为分子转子3(1×10-5M)在甲醇与二氯甲烷中荧光发射强度图;
图10为分子转子22(1×10-5M)在不同粘度条件下荧光发射强度图;
图11为分子转子22(1×10-5M)粘度条件与荧光强度的线性关系图;
图12为分子转子22(1×10-5M)在甲醇与二氯甲烷中荧光发射强度图;
图13为分子转子57(1×10-5M)在不同粘度条件下荧光发射强度图;
图14为分子转子57(1×10-5M)粘度条件与荧光强度的线性关系图;
图15为分子转子57(1×10-5M)在甲醇与二氯甲烷中荧光发射强度图;
图16为分子转子63(1×10-5M)在不同粘度条件下荧光发射强度图;
图17为分子转子63(1×10-5M)粘度条件与荧光强度的线性关系图;
图18为分子转子63(1×10-5M)在甲醇与二氯甲烷中荧光发射强度图;
图19为探针1用于细胞内碳酸酐酶检测的荧光成像图,其中A是未表达碳酸酐酶细胞,B是表达碳酸酐酶细胞。
具体实施方式
下面对本发明的实施例作详细说明,这些实施例在以本发明技术方案为前提下进行实施,给出了详细的实施方式和具体的操作过程,但本发明的保护范围不限于下述的实施例。
以下实施例中所述“分子转子”为本发明长波长发射的粘度响应性荧光染料的简称。
实施例1
2-(2-氰基-2-甲酸叔丁酯乙烯基)-5-二甲氨基-噻吩并[3,2,b]噻吩的合成(分子转子1):
Figure PCTCN2017093270-appb-000016
2-甲酰基-5-二甲氨基-噻吩并[3,2,b]噻吩的合成(化合物2):
化合物1(0.438g,2mmol)溶于15mL二甲胺的甲苯溶液,加入铜粉(6.4mg,0.01mmol),碘化亚铜(19mg,0.01mmol),磷酸三钾(0.850g,4mmol),Ar保护条件下80℃油浴加热过夜,反应完毕,冷却至室温,体系倒入50mL水中,二氯甲烷萃取3×50mL,合并有机相,旋转蒸干得粗品,无需纯化,直接用于下一步。
残余物溶于15mL二甲基甲酰胺中,冰浴条件下缓慢加入三氯氧磷(0.94ml,10mmol),撤去冰浴,体系缓慢恢复至室温,反应完毕,小心加入5ml水淬灭反应,体系倒入50mL水中,二氯甲烷萃取3×50mL,合并有机相,旋转蒸干后过柱,即得淡褐色纯化合物0.317g,产率75%。1H-NMR(400MHz,DMSO-d6):δ=9.78(s,1H),8.21(s,1H),8.05(s,1H),3.15(s,6H)。
2-(2-氰基-2-甲酸叔丁酯乙烯基)-5-二甲氨基-噻吩并[3,2,b]噻吩的合成(分子转子1):
化合物2(0.211g,1.0mmol)和氰基乙酸叔丁酯(0.169g,1.2mmol)溶于20mL无水乙醇中,加入催化量无水哌啶,Ar保护条件下油浴加热2h,反应结束,冷却至室温,旋转蒸发除去部分溶剂,体系有大量固体析出,过滤,滤饼用冷乙醇洗两次,真空烘干,即得纯的红色化合物0.310g,产率85%。1H-NMR(400MHz,DMSO-d6):δ=8.22(s,1H),8.02(s,1H),6.43(s,1H),3.15(s,6H),1.48(s,9H)。
实施例2
2-[2-氰基-2-(2-苯丙噁唑)-乙烯基]-5-二正葵氨基-噻吩并[3,2,b]噻吩的合成(分子转子2):
Figure PCTCN2017093270-appb-000017
2-甲酰基-5-二正葵氨基-噻吩并[3,2,b]噻吩的合成:
参照化合物2的合成方法,产率75%。1H-NMR(400MHz,CDCl3):δ=9.78(s,1H),8.21(s,1H),8.05(s,1H),3.32(t,4H,J=8.20Hz),1.64(m,32H),0.93(t,6H,J=8.00Hz)。
2-[2-氰基-2-(2-苯丙噁唑)-乙烯基]-5-二正葵氨基-噻吩并[3,2,b]噻吩的合成
化合物3(0.463g,1.0mmol)和2-苯并噁唑乙腈(0.189g,1.2mmol)溶于35mL无水乙醇中,加入催化量无水哌啶,氩气保护条件下油浴加热2h,反应结束,冷却至室温,旋转蒸发除去部分溶剂,体系有大量固体析出,过滤,滤饼用冷乙醇洗两次,真空烘干,即得纯的红色化合物0.495g,产率82%。1H-NMR(400MHz,DMSO-d6):δ=8.49(s,1H),8.07(s,1H),7.68-7.71(m,2H),7.35-7.38(m,2H),6.46(s,1H),3.32(t,6H,J=8.20Hz),1.66(m,32H),0.99(t,6H,J=8.00Hz)。
实施例3
2-[2-氰基-2-(1,3-苯并噻唑-2-基)-乙烯基]-5-(N-甲基-N-羟乙基)-噻吩并[3,2,b]噻吩的合成(分子转子3):
Figure PCTCN2017093270-appb-000018
化合物4:
参照化合物2的合成方法,产率75%。1H-NMR(400MHz,DMSO-d6):δ=9.78(s,1H),8.21(s,1H),8.05(s,1H),3.59(t,2H,J=5.60Hz),3.48(t,2H,J=5.60Hz),3.15(s,3H)。
2-[2-氰基-2-(1,3-苯并噻唑-2-基)-乙烯基]-5-(N-甲基-N-羟乙基)-噻吩并[3,2,b]噻吩的合成(分子转子3):
化合物4(0.241g,1.0mmol)和2-苯并噻唑乙腈(0.209g,1.2mmol)溶于35mL无水乙醇中,加入催化量无水哌啶,氩气保护条件下油浴加热2h,反应结束,冷却至室温,旋转蒸发除去部分溶剂,体系有大量固体析出,过滤,滤饼用冷乙醇洗两次,真空烘干,即得纯的红色化合物0.318g,产率87%。1H-NMR(400MHz,DMSO-d6):δ=8.45(s,1H),8.09(d,1H,J=8.00Hz),8.07(s,1H),7.94(d,1H,J=8.00Hz),7.51(m,1H),7.41(m,1H),6.45(s,1H),4.92(t,1H,J=5.60Hz),3.67(t,2H,J=5.60Hz),3.49(t,2H,J=5.60Hz),3.13(s,3H)。
实施例4
6-(2,2-二氰基-乙烯基)-2-[N-甲基-N-(3-磺酸丙氧乙基)]-噻吩并[3,2,b]噻吩的合成(分子转子4):
Figure PCTCN2017093270-appb-000019
化合物5
化合物4(0.482g,2.0mmol)于50ml圆底烧瓶中,加入25ml无水DMF溶解,Ar保护0℃条件下加入60%NaH(0.12g,2.5mmol)搅拌30min,加入丙磺酸内酯0.5ml,体系逐渐恢复至室温,反应完毕,加水2ml淬灭反应,加水100ml,异丙醇∶二氯甲烷=1∶1溶液萃取三次,合并有机相,Na2SO4干燥,过滤除去Na2SO4,旋转蒸干,残余物反相柱分离得淡黄色固体0.62g,产率85%。1H-NMR(400MHz,DMSO-d6):δ=9.78(s,1H),8.21(s,1H),8.05(s,1H),3.68(m,4H),3.55(m,2H),3.35(m,2H),3.11(s,3H),2.42(m,2H)。
6-(2,2-二氰基-乙烯基)-2-[N-甲基-N-(3-磺酸丙氧乙基)]-噻吩并[3,2,b]噻吩的合成(分子转子4)
化合物5(0.363g,1.0mmol)和丙二腈(0.079g,1.2mmol)溶于20mL无水乙醇中,加入催化量无水哌啶,Ar保护条件下油浴加热2h,反应结束,冷却至室温,旋转蒸发除掉部分溶剂,体系有大量固体析出,过滤,滤饼用冷乙醇洗两次,真空烘干,即得纯的红色化合物0.310g,产率85%。1H-NMR(400MHz,CDCl3):8.21(s,1H),8.05(s,1H),3.68(m,4H),3.55(m,2H),3.35(m,2H),3.11(s,3H),2.42(m,2H)。
实施例5
6-(2-氰基-2-甲酸)-2-甲氨基-噻吩并[3,2,b]噻吩的合成(分子转子5):
Figure PCTCN2017093270-appb-000020
2-甲酰基-5-甲氨基-噻吩并[3,2,b]噻吩(化合物6)的合成:
参照化合物2的合成方法,产率58%。1H-NMR(400MHz,CDCl3):δ=9.81(s,1H),8.21(s,1H),8.05(s,1H),3.18(s,3H)。
2-(2-氰基-2-甲酸)-5-甲氨基-噻吩并[3,2,b]噻吩的合成:
化合物6(0.200g,1.0mmol)和氰基乙酸(0.101g,1.2mmol)溶于20mL无水乙醇中,加入催化量无水哌啶,Ar保护条件下油浴加热2h,反应结束,冷却至室温,体系有大量固体析出,过滤,滤饼用冷乙醇洗两次,真空烘干,即得纯的红色化合物0.24g,产率91%。1H-NMR(400MHz,DMSO-d6):δ=11.22(s,1H),δ=8.22(s,1H),8.02(s,1H),6.43(s,1H),3.16(s,3H)。
实施例6
Figure PCTCN2017093270-appb-000021
化合物8的合成:
化合物6(1.0g,5mmol)溶于100mL乙腈中,加入碳酸钾(1.4g,10mmol),化合物7(2.47g,6mol)Ar保护条件下油浴加热回流过夜,反应完毕,冷却至室温,过滤,旋转蒸干溶剂,残余物溶于二氯甲烷,水洗3次,无水硫酸钠干燥,过滤除去Na2SO4,旋转蒸干后过柱,即得淡褐色纯化合物1.29g,产率59%。1H-NMR(400MHz,CDCl3): δ=9.78(s,1H),8.21(s,1H),8.05(s,1H),3.52-3.65(m,20H),3.37(s,3H),2.97(s,3H)。
分子转子6的合成:
化合物8(0.43g,1mmol)溶于50ml无水乙醇中,加入化合物9(参照文献公开方法L.X.Wu,K.Burgess,J.Am.Chem.Soc.2008,130,4089-4096.)(0.11g,1.2mmol),加入哌啶2滴,Ar保护条件下油浴加热回流,反应完毕,冷却至室温,旋转蒸干后过柱,即得淡褐色纯化合物0.436g,产率83%。1H-NMR(400MHz,CDCl3):δ=8.22(s,1H),8.02(s,1H),6.43(s,1H),3.52-3.65(m,20H),3.37(s,3H),2.97(s,3H)。
实施例7
Figure PCTCN2017093270-appb-000022
化合物10的合成:
化合物6(1.0g,5mmol)溶于100mL六氟异丙醇中,加入丙烯腈(0.53g,10mmol),Ar保护条件下室温搅拌,反应完毕,旋转蒸干后过柱,得红褐色固体1.15g,产率92%。1H-NMR(400MHz,CDCl3):δ=9.95(s,1H),8.22(s,1H),8.02(s,1H),3.72(t,J=6.9Hz,2H),3.03(s,3H),2.57(t,J=6.9Hz,2H)。
分子转子7
化合物10(0.25g,1mmol)溶于25ml无水乙醇中,加入化合物11(参照公开方法WO 2004020412(A1),2004.03.11)(0.17g,1.2mmol),加入哌啶2滴,Ar保护条件下油浴加热回流,反应完毕,冷却至室温,旋转蒸干后过柱,得红褐色固体0.30g,产率80%。1H-NMR(400MHz,CDCl3):δ=8.22(s,1H),8.02(s,1H),6.43(s,1H),3.72(t,J=6.9Hz,2H),3.67(t,2H,J=5.60Hz),3.35(t,2H,J=5.60Hz),3.27(s,3H),3.01(s,3H),3.11(t,2H,J=7.60Hz),2.57(t,J=6.9Hz,2H)。
实施例8
Figure PCTCN2017093270-appb-000023
化合物12的合成:
参照化合物2的合成方法,产率51%。1H-NMR(400MHz,CDCl3):δ=9.95(s,1H),8.22(s,1H),8.02(s,1H),3.12-3.09(t,J=7.5Hz,2H),1059-1.65(m,14H),0.89(t,J=7.5Hz,3H)。
化合物13的合成:
按照文献L.X.Wu et.al.J.Am.Chem.Soc.2008,130,4089-4096.公布方法合成。1H-NMR(400MHz,CDCl):δ=7.63-7.48(m,5H),4.27(s,2H),3.13(s,3H)。
分子转子8的合成:
参照分子转子6的合成方法,产率88%。1H-NMR(400MHz,CDCl3):δ=8.25(s,1H),8.09(s,1H),7.63-7.48(m,5H),6.43(s,1H),3.19(s,3H)3.12-3.09(t,J=7.5Hz,2H),1059-1.65(m,14H),0.89(t,J=7.5Hz,3H)。
实施例9
Figure PCTCN2017093270-appb-000024
化合物14的合成:
参照化合物8的合成,产率56%。1H-NMR(400MHz,CDCl3):δ=9.95(s,1H),8.22(s,1H),8.02(s,1H),3.52-3.65(m,20H),3.37(s,3H),3.12-3.09(t,J=7.5Hz,2H),1.59-1.65(m,14H),0.89(t,J=7.5Hz,3H)。
化合物15的合成:
参照分子转子6的合成,产率89%。1H-NMR(400MHz,CDCl3):δ=8.22(s,1H),8.02(s,1H),6.8(s,1H),3.52-3.65(m,20H),3.37(s,3H),3.12-3.09(t,J=7.5Hz,2H),3.01(s,3H),2.15(s,3H),1.59-1.65(m,14H),0.89(t,J=7.5Hz,3H)。
分子转子9的合成:
化合物15(0.652g,1mmol)溶于150ml无水甲苯中,加入苯甲醛(0.212g,2mmol)和催化量ZnCl2,Ar保护条件下油浴加热回流24h,冷却至室温,倒入300ml食盐水中,乙酸乙酯萃取三次,合并有机相,无水硫酸钠干燥,过滤除去Na2SO4,旋转蒸干后过柱,得紫黑色固体0.259g,产率39%。1H-NMR(400MHz,CDCl3):δ=8.22(s,1H),8.02(s,1H),7.64(d,J=8.10Hz,1H),7.21(d,J=8.10Hz,1H),7.19-7.11(m,5H),6.8(s,1H),3.52-3.65(m,20H),3.37(s,3H),3.12-3.09(t,J=7.5Hz,2H),3.01(s,3H),2.15(s,3H),1.59-1.65(m,14H),0.89(t,J=7.5Hz,3H)。
实施例10
Figure PCTCN2017093270-appb-000025
化合物16的合成:
噻吩并[3,2-b]噻吩(1.40g,10mmol)溶于120ml无水四氢呋喃中,冷却至-30℃,Ar保护条件下缓慢滴加入1.6M正丁基锂(7.5ml,12mmol),搅拌30min,缓慢加入5ml硼酸三甲酯,体系缓慢升至室温搅拌过夜,次日加水淬灭,体系倒入100ml饱和食盐水中,分出有机相,二氯甲烷萃取两次,合并有机相,无水硫酸钠干燥,过滤除去Na2SO4,旋转蒸干后过柱得白色粉末状固体1.72g,产率81%。1H-NMR(400MHz,CDCl3):δ=7.92(s,1H),7.63(d,J=5.1Hz),7.31(d,J=5.3Hz,1H),3.51(s,6H)。
化合物18的合成:
化合物16(2.12g,10mmol)溶于50ml无水四氢呋喃中,冷却至-78℃,Ar保护条件下缓慢滴加入1.6M正丁基锂(7.5ml,12mmol),搅拌2h,加入化合物18(参照文献公开方法:F.H.Wang et.al.Organmetallics,2015,34,86-93.)(3.14g,20mmol),-78℃条件下搅拌30min,缓慢升至室温,搅拌过夜,稀盐酸酸化体系至pH为3.5,体系倒入200ml饱和食盐水中,乙酸乙酯萃取,合并有机相,无水硫酸钠干燥,过滤除去Na2SO4,旋转蒸干后过柱,得淡黄色固体1.48g,产率61%。1H-NMR(400MHz,CDCl3):δ=7.92(s,1H),7.63(d,J=5.1Hz),7.31(d,J=5.3Hz,1H),3.51(s,6H),1.31 (s,6H)。
分子转子10的合成:
化合物18(1.21g,5mmol)溶于无水甲醇中,加入甲醇钠(1.35g,25mmol)丙二腈(1.65g,25ml)60℃油浴加热5h,反应完毕,冷却至室温,加水淬灭,体系倒入150ml水中,稀盐酸酸化体系至pH为2.0,二氯甲烷萃取,合并有机相,无水硫酸钠干燥,过滤除去Na2SO4,旋转蒸干后过柱,得黄色固体0.45,产率31%。1H-NMR(400MHz,CDCl3):δ=7.92(s,1H),7.63(d,J=5.1Hz),7.31(d,J=5.3Hz,1H),3.51(s,6H),1.34(s,6H)。
实施例11
6-(2-氰基-2-甲酸叔丁酯乙烯基)-2-二甲氨基-噻吩并[3,2-B:2′,3′-D]噻吩的合成(分子转子11):
Figure PCTCN2017093270-appb-000026
2-溴-6醛基-噻吩并[3,2-B:2′,3′-D]噻吩
参照文献WO2009152165(A2),2009.12.17.公开的方法进行合成。1H-NMR(400MHz,DMSO-d6):δ=7.84(s,1H),7.37(s,1H),7.24(s,1H),3.15(s,6H)。
2-N,N-二甲基-6醛基-噻吩并[3,2-B:2′,3′-D]噻吩
参照化合物2的合成,产率51%。1H-NMR(400MHz,DMSO-d6):δ=10.04(s,1H),7.84(s,1H),7.24(s,1H),3.15(s,6H)。
6-(2-氰基-2-甲酸叔丁酯乙烯基)-2-二甲氨基-噻吩并[3,2-B:2′,3′-D]噻吩的合成(分子转子11):
参照分子转子1的合成,产率85%。1H-NMR(400MHz,DMSO-d6):δ=8.45(s,1H),7.85(s,1H),6.45(s,1H),3.15(s,6H),1.48(s,9H)。
实施例12
6-[2-氰基-2-(2-苯丙噁唑)-乙烯基]-2-二甲氨基-噻吩并[3,2-B:2′,3′-D]噻吩的合成(分子转子12):
Figure PCTCN2017093270-appb-000027
化合物21:
参照化合物2的合成,产率67%。1H-NMR(400MHz,DMSO-d6):δ=10.0(s,1H),7.84(s,1H),7.24(s,1H),3.82(t,2H,J=7.8Hz),(t,2H,J=7.8Hz),3.15(s,6H)。
化合物22:
化合物21(0.648g,2.0mmol)于100ml圆底烧瓶中,加入60ml无水丙酮溶剂,加入1ml碘甲烷,Ar保护条件下室温搅拌,反应完毕,倾出上清液,沉淀反向色谱纯化得固体0.75g,产率80%。1H-NMR(400MHz,DMSO-d6):δ=10.1(s,1H),7.84(s,1H),7.24(s,1H),4.03(t,2H,J=7.8Hz),(t,2H,J=7.8Hz),3.29(s,6H),3.19(s,5H),2.52(m,2H)。
6-[2-氰基-2-(2-苯丙噁唑)-乙烯基]-2-二甲氨基-噻吩并[3,2-B:2′,3′-D]噻吩的合成:
参照分子转子2的合成,产率81%。1H-NMR(400MHz,DMSO-d6):δ=8.49(s,1H),7.85(s,1H),7.68-7.71(m,2H),7.35-7.38(m,2H),6.46(s,1H),7.84(s,1H),7.24(s,1H),4.03(t,2H,J=7.8Hz),(t,2H,J=7.8Hz),3.29(s,6H),3.19(s,5H),2.41(m,2H)。
实施例13
6-[2-氰基-2-(1,3-苯并噻唑-2-基)-乙烯基]-2-N-甲氨基-N-乙酸-二噻吩[3,2-B:2′,3′-D]噻吩的合成(分子转子13)
Figure PCTCN2017093270-appb-000028
化合物23:
参照化合物2的合成,产率41%。1H-NMR(400MHz,DMSO-d6):δ=10.04(s,1H),7.84(s,1H),7.24(s,1H),4.12(s,2H),3.15(s,3H)。
6-[2-氰基-2-(1,3-苯并噻唑-2-基)-乙烯基]-2-二甲氨基-二噻吩[3,2-B:2′,3′-D]噻吩的合成
参照分子转子3的合成,产率78%。1H-NMR(400MHz,DMSO-d6):δ=8.09(d,1H,J=8.00Hz),7.94(d,1H,J=8.00Hz),7.84(s,1H),7.57(s,1H),7.51(m,1H),7.41(m,1H),6.45(s,1H),4.92(t,1H,J=5.60Hz),4.12(s,2H),3.15(s,3H)。
实施例14
6-[2-氰基-2-(1,3-苯并噻唑-2-基)-乙烯基]-2-二甲氨基-噻吩并[3,2-B:2′,3′-D]噻吩的合成(分子转子14):
Figure PCTCN2017093270-appb-000029
6-[2-氰基-2-(1,3-苯并噻唑-2-基)-乙烯基]-2-二甲氨基-噻吩并[3,2-B:2′,3′-D]噻吩的合成
参照分子转子4的合成,产率87%。1H-NMR(400MHz,DMSO-d6):δ=7.84(s,1H),7.24(s,1H),6.45(s,1H),3.15(s,6H)。
实施例15
Figure PCTCN2017093270-appb-000030
化合物24的合成:
参照化合物2的合成方法:1H-NMR(400MHz,DMSO-d6):δ=9.97(s,1H),7.85(s,1H),7.24(s,1H),3.41(t,J=5.5Hz,4H),2.12(t,J=5.5Hz,4H)。
分子转子15的合成:
参照分子转子7的合成方法,产率91%。1H-NMR(400MHz,DMSO-d6):δ=7.85(s,1H),7.24(s,1H),6.94(s,1H),6.50(s,1H),3.48-3.52(m,4H),3.41(t,J=5.5Hz,4H),3.38(s,3H),2.12(t,J=5.5Hz,4H)。
实施例16
Figure PCTCN2017093270-appb-000031
化合物25的合成:
参照文献公开的合成方法:H.Wang et.al.Tetrahedron Letters.2007,48,3471-3474.1H-NMR(400MHz,DMSO-d6):δ=4.56-4.14(m,4H),3.91-3.37(m,8H),3.19(s,3H).
化合物26的合成:
参照化合物2的合成方法:1H-NMR(400MHz,DMSO-d6):δ=7.84(s,1H),7.24(s,1H),6.42(s,1H),6.02(d,1H),4.56-4.14(m,4H),3.91-3.37(m,8H),3.19(s,3H).
分子转子16的合成:
参照分子转子5的合成:1H-NMR(400MHz,DMSO-d6):δ=11.01(s,1H),δ=7.84(s,1H),7.24(s,1H),6.42(s,1H),6.02(d,1H),4.56-4.14(m,4H),3.91-3.37(m,8H),3.19(s,3H).
实施例17
Figure PCTCN2017093270-appb-000032
化合物27的合成:
参照化合物2的合成:1H-NMR(400MHz,DMSO-d6):δ=7.84(s,1H),7.24(s,1H),6.42(s,1H),4.14(s,4H).
分子转子17的合成:
参照分子转子1的合成方法:1H-NMR(400MHz,CDCl3):δ=7.84(s,1H),7.24(s,1H),6.42(s,1H),4.14(s,4H),4.01(s,3H).
实施例18
Figure PCTCN2017093270-appb-000033
化合物28的合成:
参照化合物2的合成方法:1H-NMR(400MHz,CDCl3):δ=9.95(s,1H),7.84(s,1H),7.24(s,1H),3.52-3.65(m,60H),3.37(s,3H)。
分子转子18的合成:
参照分子转子6的合成,产率90%,1H-NMR(400MHz,CDCl3):δ=7.84(s,1H),7.24(s,1H),6.98(s,1H),3.52-3.65(m,60H),3.37(s,3H),3.0(s,3H),2.15 (s,3H)。
实施例19
Figure PCTCN2017093270-appb-000034
化合物29的合成:
参照化合物2的合成,产率54%。1H-NMR(400MHz,CDCl3):δ=9.95(s,1H),7.84(s,1H),7.24(s,1H),3.59(t,4H,J=5.60Hz),3.48(t,4H,J=5.60Hz)。
分子转子19的合成:
参照分子转子8的合成,产率89%。1H-NMR(400MHz,CDCl3):δ=7.84(s,1H),7.63-7.58(m,5H),7.24(s,1H),3.59(t,4H,J=5.60Hz),3.48(t,4H,J=5.60Hz),3.13(s,3H)。
实施例20
Figure PCTCN2017093270-appb-000035
化合物30的合成:
化合物29(0.327g,1mmol)溶于25ml无水二氯甲烷中,冷却至0℃,Ar保护条件下缓慢滴加二氯亚砜(0.22ml,3mmol)的5ml无水二氯甲烷溶液,加毕缓慢升至室温,搅拌2h,旋转蒸发除去溶剂,残余物溶于二氯甲烷,饱和食盐水洗涤三次,有机相用无水硫酸钠干燥,过滤除去Na2SO4,旋转蒸干后过柱,得紫黑色固体0.298g,产率82%。1H-NMR(400MHz,CDCl3):δ=9.95(s,1H),7.84(s,1H),7.24(s,1H),3.69(t,4H,J=5.60Hz),3.28(t,4H,J=5.60Hz)。
分子转子20的合成:
参照分子转子9的合成,产率41%。1H-NMR(400MHz,CDCl3):δ=8.0(d,J=16.0Hz,1H),7.91(d,J=8.5Hz,2H),7.84(s,1H),7.38-7.45(m,3H),7.24(s,1H),7.15(d,J=16.0Hz,1H),6.98(s,1H),3.69(t,4H,J=5.60Hz),3.28(t,4H,J=5.60Hz),3.13(s,3H)。
实施例21
Figure PCTCN2017093270-appb-000036
化合物31的合成:
参照化合物2的合成,产率61%。1H-NMR(400MHz,CDCl3):δ=9.95(s,1H),7.84(s,1H),7.24(s,1H),3.94-3.76(m,4H),3.42-3.26(m,4H)。
分子转子21的合成:
按照分子转子1的合成方法,产率92%。1H-NMR(400MHz,CDCl3):δ=7.84(s,1H),7.24(s,1H),6.98(s,1H),3.71(q,J=5.80Hz,2H),3.59(t,4H,J=5.60Hz),3.48(t,4H,J=5.60Hz),1.25(t,J=5.80Hz,3H)。
实施例22
分子转子22的合成:
Figure PCTCN2017093270-appb-000037
化合物33的合成
参照化合物2的合成方法,产率47%。1H-NMR(400MHz,CDCl3):δ=9.92(s,1H),7.81(s,1H),7.68(d,J=9.0Hz,1H),6.92(d,J=2.0Hz,1H),6.82(d,J=9.1,2.3Hz,1H),3.21(s,6H)。
分子转子22
参照分子转子1的合成,产率91%。1H-NMR(400MHz,CDCl3):δ=8.20(s,1H),7.81(s,1H),7.68(d,J=9.0Hz,1H),6.92(d,J=2.0Hz,1H),6.82(d,J=9.1,2.3Hz,1H),3.21(s,6H),1.51(s,9H)。
实施例23
分子转子23的合成:
Figure PCTCN2017093270-appb-000038
化合物34的合成:
参照化合物2的合成方法:1H-NMR(400MHz,CDCl3):δ=9.92(s,1H),7.81(s,1H),7.68(d,J=9.0Hz,1H),6.92(d,J=2.0Hz,1H),6.82(d,J=9.1,2.3Hz,1H),3.61(t,J=8.0Hz,3H),3.34(t,J=8.0Hz,3H),3.21(s,3H)。
分子转子23的合成
参照分子转子2的合成,产率93%。1H-NMR(400MHz,DMSO-d6):δ=8.45(s,1H),8.09(d,J=8.00Hz,2H),8.07(s,1H),7.94(d,J=8.00Hz,2H),7.51(m,1H),7.41(m,1H),6.45(s,1H),3.61(t,3H,J=8.0Hz),3.34(t,J=8.0Hz,3H),3.21(s,3H)。
实施例24
Figure PCTCN2017093270-appb-000039
化合物35的合成:
参照化合物2的合成方法:1H-NMR(400MHz,CDCl3):δ=9.92(s,1H),7.81(s,1H),7.68(d,J=9.0Hz,1H),6.92(d,J=2.0Hz,1H),6.82(d,J=9.1,2.3Hz,1H),3.63(t,J=8.0Hz,4H),3.37(t,J=8.0Hz,4H)。
分子转子24的合成:
参照分子转子3的合成,产率91%。1H-NMR(400MHz,DMSO-d6):δ=8.09(d,1H,J-8.00Hz),7.94(d,1H,J-8.00Hz),7.81(s,1H),7.68(d,J-9.0Hz,1H),7.51(m,1H),7.41(m,1H),6.92(d,J=2.0Hz,1H),6.82(d,J=9.1,2.3Hz,1H),6.45(s,1H),3.63(t,J=8.0Hz,4H),3.37(t,J=8.0Hz,4H)。
实施例25
Figure PCTCN2017093270-appb-000040
化合物36的合成:
参照化合物2的合成,产率31%,1H-NMR(400MHz,CDCl3):δ=9.92(s,1H),7.81(s,1H),7.68(d,J=9.0Hz,1H),6.92(d,J=2.0Hz,1H),6.82(d,J=9.1,2.3Hz,1H),3.32(t,4H,J=8.20Hz),1.64(m,32H),0.93(t,6H,J=8.00Hz)。
分子转子25的合成:
参照分子转子4的合成,产率88%。1H-NMR(400MHz,CDCl3):δ=7.81(s,1H),7.68(d,J=9.0Hz,1H),7.31(s,1H),6.92(d,J=2.0Hz,1H),6.82(d,J=9.1,2.3Hz,1H),3.32(t,4H,J=8.20Hz),1.64(m,32H),0.93(t,6H,J=8.00Hz)。
实施例26
Figure PCTCN2017093270-appb-000041
化合物37的合成:
化合物34(0.235g,1mmol)溶于25ml无水二甲基甲酰胺中,冰浴条件下加入60%氢化钠(0.06g,1.5mmol)搅拌30min,加入β-丙内酯,体系缓慢升至室温,反应完毕,加水淬灭反应,旋蒸干燥后过柱,得淡黄色固体0.24g,产率78%。1H-NMR(400MHz,DMSO-d6):δ=9.92(s,1H),7.81(s,1H),7.68(d,J=9.0Hz,1H),6.92(d,J=2.0Hz,1H),6.82(d,J=9.1,2.3Hz,1H),3.82(t,J=5.7Hz,2H),3.54(t,J=7.2Hz,2H),3.42(t,J=7.2Hz,2H),2.65(t,J=5.7Hz,2H)。
分子转子26的合成:
参照分子转子8的合成,产率88%。1H-NMR(400MHz,DMSO-d6):δ=7.81(s,1H),7.68(d,J=9.0Hz,1H),7.63-7.48(m,5H),6.92(d,J=2.0Hz,1H),6.82(d,J=9.1,2.3Hz,1H),3.82(t,J=5.7Hz,2H),3.54(t,J=7.2Hz,2H),3.42(t,J=7.2Hz,2H),3.13(s,3H),2.65(t,J=5.7Hz,2H)。
实施例27
Figure PCTCN2017093270-appb-000042
化合物38的合成:
参照文献H.Wang et.al.Tetrahedron letters.2007.48.3471-3474.1H-NMR(400MHz,CDCl3):δ=9.92(s,1H),7.81(s,1H),7.68(d,J=9.0Hz,1H),6.92(d,J=2.0Hz,1H),6.82(d,J-9.1,2.3Hz,1H),4.09(m,1H),3.83(m,1H),3.663.52(m,5H),3.00(s,3H),2.21(s,3H),1.86(s,6H),1.67(m,2H),1.42(m,2H),1.02(t,J=5.0Hz,3H)。
分子转子27的合成:
化合物38(0.205g,1.0mmol)于50ml圆底烧瓶中,加入化合物9(参照文献公 开方法L.X.Wu,K.Burgess,J.Am.Chem.Soc.2008,130,4089-4096.)(0.11g,1.2mmol)和催化量无水氯化锌,加入20ml无水乙醇溶解,Ar保护条件下油浴加热回流,反应完毕,冷却至室温,旋转蒸发除去部分溶剂,残余物过滤,冷乙醇洗涤滤饼,真空干燥得产物0.24g,产率80%。1H-NMR(400MHz,CDCl3):δ=7.81(s,1H),7.68(d,J=9.0Hz,1H),6.92(d,J=2.0Hz,1H),6.82(d,J=9.1,2.3Hz,1H),4.09(m,1H),3.83(m,1H),3.66-3.52(m,5H),3.00(s,3H),2.21(s,3H),1.86(s,6H),1.67(m,2H),1.42(m,2H),1.02(t,J=5.0Hz,3H)。
实施例28
Figure PCTCN2017093270-appb-000043
化合物39的合成:
参照文献H.Wang et.al.Tetrahedron letters.2007.48.3471-3474.1H-NMR(400MHz,CDCl3):δ=9.92(s,1H),7.81(s,1H),7.68(d,J=9.0Hz,1H),6.92(d,J=2.0Hz,1H),6.82(d,J=9.1,2.3Hz,1H),3.63(t,J=8.0Hz,2H),3.37(t,J=8.0Hz,2H),3.00(s,3H),2.21(s,3H),1.86(s,6H),1.67(m,2H),1.42(m,2H),1.02(t,J=5.0Hz,3H)。
分子转子28的合成:
按照分子转子9的合成方法,产率29%。1H-NMR(400MHz,CDCl3):δ=8.00(d,J=16.0Hz,1H),7.85(d,J=8.0Hz,2H),7.81(s,1H),7.68(d,J=9.0Hz,1H),7.38-7.45(m,3H),7.24(d,J=16.0Hz,1H),6.92(d,J=2.0Hz,1H),6.82(d,J=9.1,2.3Hz,1H),3.63(t,J=8.0Hz,2H),3.37(t,J=8.0Hz,2H),3.00(s,3H),2.21(s,3H),1.86(s,6H),1.67(m,2H),1.42(m,2H),1.02(t,J=5.0Hz,3H)。
实施例29
Figure PCTCN2017093270-appb-000044
化合物40的合成:
参照文献公开方法:K.T.Arun et.al.J.Phys.Chem.A.2005,109,5571-5578.1H-NMR(400MHz,CDCl3):δ=9.92(s,1H),7.81(s,1H),7.68(d,J=9.0Hz,1H),6.92(d,J=2.0Hz,1H),6.82(d,J=9.1,2.3Hz,1H),3.52-3.65(m,20H),3.37(s,3H),2.97(s,3H)。
分子转子29的合成:
按照分子转子5的合成方法,产率81%,1H-NMR(400MHz,CDCl3):δ=7.81(s,1H),7.68(d,J=9.0Hz,1H),7.05(s,1H),6.92(d,J=2.0Hz,1H),6.82(d,J=9.1,2.3Hz,1H),3.52-3.65(m,20H),3.37(s,3H),2.97(s,3H)。
实施例30
Figure PCTCN2017093270-appb-000045
化合物42的合成:
参照分子转子2的合成方法,产率79%,1H-NMR(40(MHz,CDCl3):δ=9.92(s, 1H),7.81(s,1H),7.68(d,J=9.0Hz,1H),6.92(d,J=2.0Hz,1H),6.82(d,J=9.1,2.3Hz,1H),3.55(s,3H)。
分子转子30的合成:
参照分子转子7的合成方法,产率89%。1H-NMR(400MHz,CDCl3):δ=7.81(s,1H),7.68(d,J=9.0Hz,1H),6.92(d,J=2.0Hz,1H),6.82(d,J=9.1,2.3Hz,1H),3.55(s,3H),3.38(s,3H),3.48-3.52(m,4H)。
实施例31
Figure PCTCN2017093270-appb-000046
化合物43的合成:
化合物42(0.38g,2mmol)溶于25ml无水二氯甲烷中,冷却至-78℃,加入1M的三氯化硼乙醚溶液2ml,搅拌2h,体系缓慢升至室温,反应完毕,加水淬灭,体系倒入100ml饱和食盐水中,二氯甲烷萃取三次,合并有机相,无水硫酸钠干燥,过滤除去Na2SO4,旋转蒸干后过柱,得白色固体0.34g,产率88%。1H-NMR(400MHz,CDCl3):δ=9.92(s,1H),7.81(s,1H),7.68(d,J=9.0Hz,1H),6.92(d,J=2.0Hz,1H),6.82(d,J=9.1,2.3Hz,1H)。
分子转子31的合成:
参照分子转子1的合成,产率91%。1H-NMR(400MHz,CDCl3):δ=7.81(s,1H),7.68(d,J=9.0Hz,1H),7.01(s,1H),6.92(d,J=2.0Hz,1H),6.82(d,J=9.1,2.3Hz,1H),3.61(s,3H),3.55(s,3H)。
实施例32
分子转子32的合成:
Figure PCTCN2017093270-appb-000047
化合物45
化合物44(0.40g,2mmol)溶于100ml无水二氯甲烷中,冷却至-78℃,分批加入NBS(0.36g,2mmol),Ar保护条件下搅拌2h,恢复至室温,搅拌过夜,反应完毕,加水10ml淬灭反应,过滤,有机相用饱和食盐水洗涤,合并有机相,Na2SO4干燥,选干过柱,得淡黄色固体0.45g,产率80%。1H-NMR(400MHz,CDCl3):δ=6.57(s,1H),4.28(s,3H),3.93(s,3H)。
化合物46
参照化合物2的合成,产率25%。1H-NMR(400MHz,CDCl3):δ=10.0(s,1H),6.54(s,1H),4.28(s,3H),3.87(s,3H),3.12(s,6H)。
分子转子32
参照分子转子1的合成,产率86%。1H-NMR(400MHz,CDCl3):δ=6.55(s,1H),4.29(s,3H),3.88(s,3H),3.13(s,6H),1.51(s,9H)。
实施例33
Figure PCTCN2017093270-appb-000048
分子转子33的合成:
化合物46(0.27g,1mmol)于50mL圆底烧瓶中,加入氰基乙酸(0.102g,1.2mmol),加如30mL无水乙醇溶解,加入催化量无水氯化锌,氩气保护条件下油浴加热回流,反应完毕冷却至室温,选出部分溶剂,析出大量固体,过滤,滤饼用冰乙醇洗涤,真空干燥得产物0.28g,产率92%。1H-NMR(400MHz,CDCl3):δ=6.55(s,1H),4.29(s,3H),3.88(s,3H),3.13(s,6H)。
实施例34:
Figure PCTCN2017093270-appb-000049
化合物47的合成:
化合物32(0.43g,2mmol)溶于50ml干燥的二卤甲烷中,加入醋酸钾(0.4g,4mmol),冰浴条件下加入溴素(0.32g,2mmol),缓慢升至室温,反应完毕,加入饱和硫代硫酸钠溶液100ml,分出有机相,水相用二氯甲烷萃取三次,合并有机相,旋转蒸干后过柱,得黄色产物0.64g,产率81%。1H-NMR(400MHz,CDCl3):δ=7.81(s,1H),7.68(d,J=9.0Hz,1H),6.92(d,J=2.0Hz,1H)。
化合物48的合成:
化合物47(1.27g,3.43mmol)溶于50ml干燥的三乙胺中,加入二氯二四三苯基膦钯(120.2mg,0.171mmol),碘化亚铜(65.2mg,0.343mmol)和三甲基硅乙炔(344mg,3.43mmol),Ar保护条件下油浴加热24h,反应完毕,加水5ml淬灭反应,旋转蒸干溶剂,残余物溶于乙醚,过滤,旋转蒸干得粗品,无需纯化,直接用于下一步。
粗品溶于30ml NMP中,加入九水合硫化钠(0.87g,3.63mmol),Ar保护条件下190℃油浴加热12h,冷却至室温,加入20ml饱和氯化铵溶液,二氯甲烷萃取三次,合并有机相,Na2SO4干燥有机相,过滤除去Na2SO4,旋转蒸干后过柱,得白色固体0.85g,产率49%。1H-NMR(400MHz,CDCl3):δ=7.87(m,1H),7.71(m,1H),7.51(d,J=5.4Hz,1H),7.41(m,1H),7.32(d,J=5.4Hz,1H)。
化合物49的合成:
参照化合物2的合成方法,产率44%。1H-NMR(400MHz,CDCl3):δ=9.71(s,1H),7.87(m,1H),7.71(m,1H),7.51(d,J=5.4Hz,1H),7.32(d,J=5.4Hz,1H),3.01(s,6H)。
分子转子34的合成:
参照分子转子4的合成,产率95%。1H-NMR(400MHz,CDCl3):δ=7.87(m,1H),7.71(m,1H),7.51(d,J=5.4Hz,1H),7.32(d,J=5.4Hz,1H),7.01(s,1H)。
实施例35:
Figure PCTCN2017093270-appb-000050
化合物50的合成:
参照化合物4的合成方法,产率78%,1H-NMR(400MHz,CDCl3):δ=9.71(s,1H),7.87(m,1H),7.71(m,1H),7.51(d,J=5.4Hz,1H),7.32(d,J=5.4Hz,1H),3.59(t,2H,J=5.60Hz),3.48(t,2H,J=5.60Hz),3.15(s,3H)。
分子转子35的合成:
参照分子转子1的合成方法,产率78%,1H-NMR(400MHz,CDCl3):δ=7.87(m,1H),7.71(m,1H),7.51(d,J=5.4Hz,1H),7.32(d,J=5.4Hz,1H),7.01(s,1H),3.59(t,2H,J=5.60Hz),3.48(t,2H,J=5.60Hz),3.15(s,3H),1.49(s,9H)。
实施例36:
Figure PCTCN2017093270-appb-000051
化合物51的合成:
参照化合物2的合成方法,产率51%。1H-NMR(400MHz,CDCl3):δ=9.71(s,1H),7.87(m,1H),7.71(m,1H),7.51(d,J=5.4Hz,1H),7.32(d,J=5.4Hz,1H),3.55(t,4H,J=5.60Hz),3.46(t,4H,J=5.60Hz)。
分子转子36的合成:
参照分子转子7的合成,产率89%。1H-NMR(400MHz,CDCl3):δ=7.87(m,1H),7.71(m,1H),7.51(d,J=5.4Hz,1H),7.32(d,J=5.4Hz,1H),7.03(s,1H),3.55(t,4H,J=5.60Hz),3.46-3.52(m,4H),3.46(t,4H,J=5.60Hz),3.38(s,3H)。
实施例37:
Figure PCTCN2017093270-appb-000052
化合物52的合成:
参照化合物2的合成,产率21%。1H-NMR(400MHz,CDCl3):δ=9.71(s,1H),7.87(m,1H),7.71(m,1H),7.51(d,J=5.4Hz,1H),7.32(d,J=5.4Hz,1H),3.18(s,3H)。
分子转子37的合成:
参照分子转子5的合成,产率93%。1H-NMR(400MHz,CDCl3):δ=7.87(m,1H),7.71(m,1H),7.51(d,J=5.4Hz,1H),7.32(d,J=5.4Hz,1H),7.03(s,1H)3.18(s,3H)。
实施例38:
Figure PCTCN2017093270-appb-000053
化合物53的合成:
参照化合物8的合成方法,产率75%。1H-NMR(400MHz,CDCl3):δ=9.71(s,1H),7.87(m,1H),7.71(m,1H),7.51(d,J=5.4Hz,1H),7.32(d,J=5.4Hz,1H),3.52-3.65(m,20H),3.37(s,3H),2.97(s,3H)。
分子转子38的合成:
参照分子转子2的合成,91%。1H-NMR(400MHz,DMSO-d6):δ=8.49(s,1H),8.07(s,1H),7.68-7.71(m,2H),7.35-7.38(m,2H),6.46(s,1H),3.52-3.65(m,20H),3.37(s,3H),2.97(s,3H)。
实施例39:
Figure PCTCN2017093270-appb-000054
化合物54的合成:
参照化合物10的合成,产率86%。1H-NMR(400MHz,CDCl3):δ=9.71(s,1H),7.87(m,1H),7.71(m,1H),7.51(d,J=5.4Hz,1H),7.32(d,J=5.4Hz,1H),3.72(t,J=6.9Hz,2H),3.03(s,3H),2.57(t,J=6.9Hz,2H)。
分子转子39的合成:
参照分子转子3的合成,产率86%。1H-NMR(400MHz,DMSO-d6):δ=7.87(m,1H),7.75(m,1H),7.68-7.71(m,2H),7.51(d,J=5.4Hz,1H),7.35-7.38(m,2H),7.32(d,J=5.4Hz,1H),6.96(s,1H),3.72(t,J=6.9Hz,2H),3.03(s,3H),2.57(t,J=6.9Hz,2H)。
实施例40:
Figure PCTCN2017093270-appb-000055
化合物55的合成:
参照化合物39的合成:1H-NMR(400MHz,CDCl3):δ=9.77(s,1H),7.87(m,1H),7.71(m,1H),7.51(d,J=5.4Hz,1H),7.32(d,J=5.4Hz,1H),3.63(t,J=8.0Hz,2H),3.37(t,J=8.0Hz,2H),3.00(s,3H),2.21(s,3H),1.86(s,6H),1.67(m,2H),1.42(m,2H),1.02(t,J=5.0Hz,3H)。
分子转子40的合成:
参照分子转子8的合成,产率88%。1H-NMR(400MHz,CDCl3):δ=7.87(m,1H),7.71(m,1H),7.63-7.48(m,6H),7.32(d,J=5.4Hz,1H),7.03(s,1H),3.63(t,J=8.0Hz,2H),3.37(t,J=8.0Hz,2H),3.13(s,3H),3.00(s,3H),2.21(s,3H),1.86(s,6H),1.67(m,2H),1.42(m,2H),1.02(t,J=5.0Hz,3H)。
实施例41:
Figure PCTCN2017093270-appb-000056
化合物56的合成:
参照文献公开的方法WO2013142841(A1),2013.09.26.1H-NMR(400MHz,CDCl3):δ=7.87(s,2H),7.54(s,1H),7.42(d,J=5.6Hz,1H),7.39(d,J=5.6Hz,1H)。
化合物57的合成:
参照化合物2的合成,产率41%。1H-NMR(400MHz,CDCl3):δ=9.99(s,1H),7.89(s,2H),7.59(s,1H),7.27(s,1H),3.09(s,6H)。
分子转子41的合成:
参照分子转子4的合成,产率81%。1H-NMR(400MHz,CDCl3):δ=7.89(s,2H),7.59(s,1H),7.27(s,1H),7.02(s,1H),3.09(s,6H)。
实施例42:
Figure PCTCN2017093270-appb-000057
化合物58的合成:
参照化合物3的合成,产率55%。1H-NMR(400MHz,CDCl3):δ=9.99(s,1H),7.89(s,2H),7.59(s,1H),7.27(s,1H),3.32(t,4H,J=8.20Hz),1.64(m,32H),0.93(t,6H,J=8.00Hz)。
分子转子42的合成:
参照化合物1的合成,产率96%。1H-NMR(400MHz,CDCl3):δ=7.89(s,2H),7.59(s,1H),7.27(s,1H),7.05(s,1H),3.32(t,4H,J=8.20Hz),1.64(m,32H),1.49(s,9H),0.93(t,6H,J=8.00Hz)。
实施例43:
Figure PCTCN2017093270-appb-000058
化合物59的合成:
参照化合物4的合成,产率65%。1H-NMR(400MHz,CDCl3):δ=9.99(s,1H),7.89(s,2H),7.59(s,1H),7.27(s,1H),3.59(t,2H,J=5.60Hz),3.48(t,2H,J=5.60Hz),3.15(s,3H)。
分子转子43的合成:
参照分子转子2的合成,产率88%。1H-NMR(400MHz,CDCl3):δ=7.89(s,2H),7.74(d,1H,J=4.0Hz),7.59(s,1H),7.55(d,1H,J=4.0Hz),7.36-7.42(m,2H),7.27(s,1H),7.00(s,1H),3.59(t,2H,J=5.60Hz),3.48(t,2H,J=5.60Hz),3.15(s,3H)。
实施例44:
Figure PCTCN2017093270-appb-000059
化合物60的合成:
参照化合物6的合成,产率55%。1H-NMR(400MHz,CDCl3):δ=10.00(s,1H),7.88(s,2H),7.60(s,1H),7.28(s,1H),3.11(s,3H)。
分子转子44的合成:
参照分子转子3的合成,产率81%。1H-NMR(400MHz,CDCl3):δ=8.04(d,1H,J=8.0Hz),7.91(d,1H,J=8.0Hz),7.88(s,2H),7.60(s,1H),7.53(t,1H,J=8.0Hz),7.45(t,1H,J=8.0Hz),7.28(s,1H),7.01(s,1H),3.11(s,3H)。
实施例45:
Figure PCTCN2017093270-appb-000060
化合物61的合成:
按照化合物8的合成方法,产率76%。1H-NMR(400MHz,CDCl3):δ=10.00(s,1H),7.88(s,2H),7.60(s,1H),7.28(s,1H),3.52-3.65(m,20H),3.37(s,3H),2.97(s,3H)。
分子转子45的合成:
按照分子转子6的合成方法,产率85%。1H-NMR(400MHz,CDCl3):δ=7.87(s,2H),7.61(s,1H),7.28(s,1H),7.02(s,1H),3.98(s,3H),3.52-3.65(m,20H),3.37(s,3H),3.01(s,3H),2.97(s,3H)。
实施例46:
Figure PCTCN2017093270-appb-000061
化合物62的合成:
参照化合物24的合成方法,产率66%。1H-NMR(400MHz,CDCl3):δ=10.01(s,1H),7.86(s,2H),7.61(s,1H),7.27(s,1H),3.41(t,4H,J=5.5Hz),2.21(t,4H,J=5.5Hz)。
分子转子46的合成:
参照分子转子7的合成方法,产率85%。1H-NMR(400MHz,CDCl3):δ=7.86(s,2H),7.61(s,1H),7.27(s,1H),7.03(s,1H),3.48-3.52(m,4H),3.41(t,4H,J=5.5Hz),3.38(s,3H),2.21(t,4H,J=5.5Hz)。
实施例47:
Figure PCTCN2017093270-appb-000062
化合物63的合成:
参照化合物10的合成方法,产率76%。1H-NMR(400MHz,CDCl3):δ=10.02(s,1H),7.86(s,2H),7.61(s,1H),7.27(s,1H),3.72(t,2H,J=8.0Hz),3.11(s,3H),2.57(t,2H,J=8.0Hz)。
分子转子47的合成:
参照分子转子5的合成方法,产率91%。1H-NMR(400MHz,CDCl3):δ=7.88(s, 2H),7.60(s,1H),7.28(s,1H),6.99(s,1H),3.72(t,2H,J=8.0Hz),3.11(s,3H),2.57(t,2H,J=8.0Hz)。
实施例48:
Figure PCTCN2017093270-appb-000063
化合物64的合成:
按照文献公开的方法(Riger Ralph et al.Chem.Mater.2000,22,5314-4318.)合成:1H-NMR(400MHz,CDCl3):δ=8.38(s,1H),8.28(s,1H),7.47(d,2H,J=5.6Hz),7.42(d,2H,J=5.6Hz)。
化合物65的合成:
按照化合物1的合成方法,产率55%。1H-NMR(400MHz,CDCl3):δ=8.38(s,1H),8.21(s,1H),7.41(m,1H),7.38(d,1H,J=5.6Hz)。
化合物66的合成:
参照化合物4的合成方法,产率55%。1H-NMR(400MHz,CDCl3):δ=9.99(s,1H),8.39(s,1H),8.22(s,1H),7.42(m,1H),7.38(d,1H,J=5.6Hz),3.59(t,2H,J=5.60Hz),3.48(t,2H,J=5.60Hz),3.15(s,3H)。
分子转子48的合成:
参照分子转子4的合成,产率95%。1H-NMR(400MHz,CDCl3):δ=8.38(s,1H),8.23(s,1H),7.42(m,1H),7.38(d,1H,J=5.6Hz),7.05(s,1H),3.59(t,2H,J=5.60Hz),3.48(t,2H,J=5.60Hz),3.15(s,3H)。
实施例49:
Figure PCTCN2017093270-appb-000064
化合物67的合成:
参照化合物5的合成,产率76%。1H-NMR(400MHz,CDCl3):δ=9.99(s,1H),8.39(s,1H),8.22(s,1H),7.42(m,1H),7.38(d,1H,J=5.6Hz),3.68(m,4H),3.55(m,2H),3.35(m,2H),3.11(s,3H),2.42(m,2H)。
分子转子49的合成:
参照分子转子1的合成方法,90%。1H-NMR(400MHz,CDCl3):δ=8.36(s,1H),8.23(s,1H),7.42(m,1H),7.38(d,1H,J=5.6Hz),7.02(s,1H),3.68(m,4H),3.55(m,2H),3.35(m,2H),3.11(s,3H),2.42(m,2H)。
实施例50:
Figure PCTCN2017093270-appb-000065
化合物68的合成:
参照化合物29的合成方法,产率58%。1H-NMR(400MHz,CDCl3):δ=10.01(s,1H),8.39(s,1H),8.22(s,1H),7.42(m,1H),7.38(d,1H,J=5.6Hz),3.59(t,4H,J=5.60Hz),3.48(t,4H,J=5.60Hz)。
分子转子50的合成:
参照分子转子6的合成方法,产率87%。1H-NMR(400MHz,CDCl3):δ=8.38(s,1H),8.20(s,1H),7.41(m,1H),7.37(d,1H,J=5.6Hz),7.00(s,1H),3.59(t,4H,J=5.60Hz),3.48(t,4H,J=5.60Hz),3.0(s,3H),2.15(s,3H)。
实施例51:
Figure PCTCN2017093270-appb-000066
化合物69的合成:
参照化合物6的合成方法,产率54%。1H-NMR(400MHz,CDCl3):δ=10.00(s,1H),8.38(s,1H),8.23(s,1H),7.63-7.48(m,5H),7.42(m,1H),7.38(d,1H,J=5.6Hz),7.00(s,1H),3.18(s,3H),3.07(s,3H)。
分子转子51的合成:
参照分子转子54的合成方法,89%。1H-NMR(400MHz,CDCl3):δ=8.38(s,1H),8.23(s,1H),7.42(m,2H),7.38(d,1H,J=5.6Hz),3.18。
实施例52:
Figure PCTCN2017093270-appb-000067
化合物70的合成:
参照化合物8的合成方法,产率66%。1H-NMR(400MHz,CDCl3):δ=10.00(s,1H),8.38(s,1H),8.23(s,1H),7.42(m,1H),7.38(d,1H,J=5.6Hz),3.52-3.65(m,20H),3.37(s,3H),2.97(s,3H)。
分子转子52的合成:
参照分子转子2的合成,产率86%。1H-NMR(400MHz,CDCl3):δ=8.38(s,1H),8.23(s,1H),7.74(d,1H,J=4.0Hz),7.55(d,1H,J=4.0Hz),7.38-7.42(m,3H),7.38(d,1H,J=5.6Hz),6.95(s,1H),3.52-3.65(m,20H),3.37(s,3H),2.97(s,3H)。
实施例53:
Figure PCTCN2017093270-appb-000068
化合物71的合成:
参照化合物10的合成方法,产率69%。1H-NMR(400MHz,CDCl3):δ=10.01(s,1H),8.39(s,1H),8.21(s,1H),7.41(m,1H),7.37(d,1H,J=5.6Hz),3.72 (t,2H,J=6.9Hz),3.03(s,3H),2.57(t,3H,J=6.9Hz)。
分子转子53的合成:
参照分子转子3的合成,产率88%。1H-NMR(400MHz,CDCl3):δ=8.36(s,1H),8.21(s,1H),8.04(d,1H,J=8.0Hz),7.90(d,1H,J=8.0Hz),7.53(t,1H,J=8.0Hz),7.45(t,1H,J=8.0Hz),7.41(m,1H),7.37(d,1H,J=5.6Hz),3.72(t,2H,J=6.9Hz),3.03(s,3H),2.57(t,3H,J=6.9Hz)。
实施例54:
Figure PCTCN2017093270-appb-000069
化合物72的合成:
参照化合物12的合成方法,产率61%。1H-NMR(400MHz,CDCl3):δ=10.01(s,1H),8.39(s,1H),8.21(s,1H),7.41(m,1H),7.37(d,1H,J=5.6Hz),3.09-3.12(m,5H),1.59-1.66(m,2H),1.27-1.41(m,14H),0.89(t,3H,J=7.0Hz)。
分子转子54的合成:
参照分子转子5的合成方法,产率86%。1H-NMR(400MHz,CDCl3):δ=8.38(s,1H),8.22(s,1H),7.42(m,1H),7.38(d,1H,J=5.6Hz),7.01(s,1H),3.09-3.12(m,5H),1.59-1.66(m,2H),1.27-1.41(m,14H),0.89(t,3H,J=7.0Hz)。
实施例55:
Figure PCTCN2017093270-appb-000070
化合物73的合成:
参照化合物21的合成方法,产率69%。1H-NMR(400MHz,CDCl3):δ=10.01(s,1H),8.39(s,1H),8.21(s,1H),7.41(m,1H),7.37(d,1H,J=5.6Hz),3.94-3.76(m,4H),3.42-3.26(m,4H)。
分子转子55的合成:
参照分子转子7的合成,产率93%。1H-NMR(400MHz,CDCl3):δ=8.39(s,1H),8.21(s,1H),7.41(m,1H),7.37(d,1H,J=5.6Hz),6.99(s,1H),3.94-3.76(m,4H),3.49-3.52(m,2H),3.42-3.26(m,4H),3.39(s,3H)。
实施例56:
Figure PCTCN2017093270-appb-000071
化合物74的合成:
按照文献Kureya,Takeshi et al.Jpn.Kokai Tokkyo Koho,2013194039.30Sep 2013.公开的方法合成。1H-NMR(400MHz,CDCl3):δ=7.24(d,2H,J=5.0Hz),7.19(d,2H,J=5.0Hz),0.46(s,6H)。
化合物75的合成:
化合物74(0.4g,1.8mmol),溶于100ml无水四氢呋喃中,冷却至-30℃,加入N-溴代二丁酰亚胺,Ar保护条件下搅拌2h,加水5ml淬灭反应,恢复至室温,旋转蒸干除去溶剂,残余物溶于100ml二氯甲烷中,水洗三次,有机相用Na2SO4干燥,过滤除去Na2SO4,旋转蒸干后过柱,得白色固体0.31g,产率57%。1H-NMR(400MHz,CDCl3):δ=7.73(s,1H),7.42(d,1H,J=4.8Hz),7.15(d,1H,J=4.8Hz),0.46(s,6H)。
化合物76的合成:
参照化合物2的合成方法,产率51%。1H-NMR(400MHz,CDCl3):δ=9.87(s,1H),7.83(s,1H),7.10(s,1H),3.1(s,6H),0.46(s,6H)。
分子转子56的合成:
按照分子转子4的合成,产率95%。1H-NMR(400MHz,CDCl3):δ=7.83(s,1H),7.10(s,1H),7.01(s,1H),3.1(s,6H),0.46(s,6H)。
实施例57:
Figure PCTCN2017093270-appb-000072
化合物77的合成:
按照化合物4的合成方法合成,产率42%。1H-NMR(400MHz,CDCl3):δ=9.88(s,1H),7.83(s,1H),7.10(s,1H),3.59(t,2H,J=5.60Hz),3.48(t,2H,J=5.60Hz),3.15(s,3H),0.46(s,6H)。
分子转子57的合成:
按照分子转子1的合成方法合成,产率96%。1H-NMR(400MHz,CDCl3):δ=7.84(s,1H),7.11(s,1H),7.03(s,1H),3.59(t,2H,J=5.60Hz),3.48(t,2H,J=5.60Hz),3.15(s,3H),1.50(s,9H),0.46(s,6H)。
实施例58:
Figure PCTCN2017093270-appb-000073
化合物78的合成:
按照化合物35的合成方法合成,产率43%。1H-NMR(400MHz,CDCl3):δ=9.89(s,1H),7.83(s,1H),7.10(s,1H),3.63(t,J=8.0Hz,4H),3.37(t,J=8.0Hz,4H),0.46(s,6H)。
分子转子58的合成:
按照分子转子5的合成方法合成,产率97%。1H-NMR(400MHz,CDCl3):δ=7.83(s,1H),7.10(s,1H),6.99(s,1H),3.63(t,J=8.0Hz,4H),3.37(t,J=8.0Hz,4H),0.46(s,6H)。
实施例59:
Figure PCTCN2017093270-appb-000074
化合物79的合成:
参照文献Huang Hui et al.Chemistry of Materials,2011,23(8),2185-2200.公开的方法合 成。1H-NMR(400MHz,CDCl3):δ=7.24(d,2H,J=5.0Hz),7.19(d,2H,J=5.0Hz),2.39(t,4H,J=9.0Hz),1.6(t,4H,J=9.0Hz)。
化合物80的合成:
按照化合物75的合成方法合成,产率51%。1H-NMR(400MHz,CDCl3):δ=7.70(s,1H),7.40(d,1H,J=4.8Hz),7.16(d,1H,J=4.8Hz),2.39(t,4H,J=9.0Hz),1.6(t,4H,J=9.0Hz)。
化合物81的合成:
参照化合物2的合成方法合成,产率45%。1H-NMR(400MHz,CDCl3):δ=9.88(s,1H),7.83(s,1H),7.10(s,1H),3.1(s,6H),2.39(t,4H,J=9.0Hz),1.6(t,4H,J=9.0Hz)。
分子转子59的合成:
按照分子转子4的合成,产率91%。1H-NMR(400MHz,CDCl3):δ=9.88(s,1H),7.83(s,1H),7.10(s,1H),3.1(s,6H),2.39(t,4H,J=9.0Hz),1.6(t,4H,J=9.0Hz)。
实施例60:
Figure PCTCN2017093270-appb-000075
化合物82的合成:
参照化合物6的合成方法合成,产率71%。1H-NMR(400MHz,CDCl3):δ=9.87(s,1H),7.85(s,1H),7.11(s,1H),3.15(s,3H),2.39(t,4H,J=9.0Hz),1.6(t,4H,J=9.0Hz)。
分子转子60的合成:
参照分子转子1的合成方法合成,产率95%。1H-NMR(400MHz,CDCl3):δ=7.85(s,1H),7.11(s,1H),7.03(s,1H),3.15(s,3H),2.39(t,4H,J=9.0Hz),1.6(t,4H,J=9.0Hz),1.49(s,9H)。
实施例61:
Figure PCTCN2017093270-appb-000076
化合物83的合成:
按照化合物10的合成方法合成,产率90%。1H-NMR(400MHz,CDCl3):δ=9.87(s,1H),7.85(s,1H),7.11(s,1H),3.72(t,J=6.9Hz,2H),3.03(s,3H),2.57(t,J=6.9Hz,2H),2.39(t,4H,J=9.0Hz),1.6(t,4H,J=9.0Hz)。
分子转子61的合成:
按照分子转子2的合成方法合成,产率89%。1H-NMR(400MHz,CDCl3):δ=7.85(s,1H),7.74(d,1H,J=4.0Hz),7.55(d,1H,J=4.0Hz),7.36-7.42(m,2H),7.11(s,1H),7.01(s,1H),3.72(t,J=6.9Hz,2H),3.03(s,3H),2.57(t,J=6.9Hz,2H),2.39(t,4H,J=9.0Hz),1.6(t,4H,J=9.0Hz)
实施例62:
Figure PCTCN2017093270-appb-000077
化合物84的合成:
按照化合物4的合成方法合成,产率61%。1H-NMR(400MHz,CDCl3):δ=9.88(s,1H),7.85(s,1H),7.11(s,1H),3.59(t,2H,J=5.60Hz),3.48(t,2H,J=5.60Hz),3.14(s,3H),2.39(t,4H,J=9.0Hz),1.6(t,4H,J=9.0Hz)。
分子转子62的合成:
按照分子转子3的合成方法合成,产率95%。1H-NMR(400MHz,CDCl3):δ=8.0((d,1H,J=8.0Hz),7.90(d,1H,J=8.0Hz),7.85(s,1H),7.53(t,1H,J=8.0Hz),7.45(t,1H,J=8.0Hz),7.11(s,1H),6.99(s,1H),3.59(t,2H,J=5.60Hz),3.48(t,2H,J=5.60Hz),3.14(s,3H),2.39(t,4H,J=9.0Hz),1.6(t,4H,J=9.0Hz)。
实施例63:
Figure PCTCN2017093270-appb-000078
化合物85的合成:
参照文献(H.G.Jeong et al.Macromol.Chem.Phys.2011,212,2308-2318)公开的方法合成:1H-NMR(400MHz,CDCl3):δ=7.75(d,J=5.2Hz,2H),7.02(d,J=5.2Hz,2H),3.90(s,3H)。
化合物86的合成:
按照化合物19的合成方法合成:1H-NMR(400MHz,CDCl3):δ=7.83(s,1H),7.75(d,J=5.2Hz,1H),7.02(d,J=5.2Hz,1H),3.90(s,3H)。
化合物87的合成:
参照化合物20的合成方法合成:1H-NMR(400MHz,CDCl3):δ=9.98(s,1H),7.63(s,1H),7.52(s,J=5.2Hz,1H),3.90(s,3H),3.03(s,6H)。
分子转子63的合成:
参照分子转子2的合成:1H-NMR(400MHz,CDCl3):δ=7.63(s,1H),7.52(s,1H),7.03(s,1H),3.90(s,3H),3.03(s,6H),1.51(s,9H)。
实施例64:
Figure PCTCN2017093270-appb-000079
化合物85的合成:
参照文献(H.G.Jeong et al.Macromol.Chem.Phys.2011,212,2308-2318)公开的方法合成:1H-NMR(400MHz,CDCl3):δ=7.78(d,J=5.6Hz,2H),7.09(d,J=5.6Hz,2H)。
化合物89的合成:
按照化合物19的合成方法合成:1H-NMR(400MHz,CDCl3):δ=7.89(s,1H),7.79(d,J=5.6Hz,1H),7.12(d,J=5.6Hz,1H)。
化合物90的合成:
参照化合物20的合成方法合成:1H-NMR(400MHz,CDCl3):δ=9.95(s,1H), 7.69(s,1H),7.59(s,J=5.2Hz,1H),3.59(t,2H,J=5.60Hz),3.48(t,2H,J=5.60Hz),3.15(s,3H)。
分子转子64的合成:
参照分子转子5的合成:1H-NMR(400MHz,CDCl3):δ=7.69(s,1H),7.58(s,1H),7.01(s,1H),3.59(t,2H,J=5.60Hz),3.48(t,2H,J=5.60Hz),3.15(s,3H),1.51(s,9H)。
实施例65:
Figure PCTCN2017093270-appb-000080
化合物91:
参照文献(Ping Yan.et al.J.Org.Chem.2008,73,6587-6594.)公开的方法合成。1H-NMR(400MHz,CDCl3):δ=7.18(s,1H),6.96(d,2H,J=5.6Hz),1.50(s,6H)。
化合物92:
参照化合物22的合成方法,产率66%。1H-NMR(400MHz,CDCl3):δ=9.89(s,1H),7.18(s,1H),6.96(d,2H,J=5.6Hz),3.10(s,6H),1.50(s,6H)。
分子转子65的合成:
参照分子转子1的合成方法,产率98%。1H-NMR(400MHz,CDCl3):δ=7.89(s,1H),7.18(s,1H),6.96(d,2H,J=5.6Hz),3.10(s,6H),1.50(m,15H)。
实施例66:
Figure PCTCN2017093270-appb-000081
分子转子66的合成:
参照分子转子2的合成方法,产率66%。1H-NMR(400MHz,CDCl3):δ=7.89(s,1H),7.74(d,1H,J=4.0Hz),7.55(d,1H,J=4.0Hz),7.36-7.42(m,2H),7.18(s,1H),6.96(d,2H,J=5.6Hz),3.10(s,6H),1.50(s,6H)。
实施例67:
Figure PCTCN2017093270-appb-000082
化合物93:
参照化合物2的合成方法,产率36%。1H-NMR(400MHz,CDCl3):δ=9.89(s,1H),7.18(s,1H),6.96(d,2H,J=5.6Hz),3.85(t,2H,J=5.6Hz),3.60(t,2H,J=5.6Hz),3.10(s,3H),1.50(s,6H)。
分子转子67的合成:
参照化合物1的合成方法,产率98%。1H-NMR(400MHz,CDCl3):δ=8.04(d,1H,J=8.0Hz),7.93(d,1H,J=8.0Hz),7.89(s,1H),7.53(t,1H,J=8.0Hz),7.45(t, 1H,J=8.0Hz),7.18(s,1H),6.96(d,2H,J=5.6Hz),4.24(s,2H),3.85(t,2H,J=5.6Hz),3.60(t,2H,J=5.6Hz),3.10(s,3H),1.50(s,6H)。
实施例68:
Figure PCTCN2017093270-appb-000083
分子转子68的合成:
参照化合物2的合成方法,产率36%。1H-NMR(400MHz,CDCl3):δ=7.89(s,1H),7.18(s,1H),6.96(d,2H,J=5.6Hz),3.10(s,6H),1.50(m,6H)。
实施例69:
探针1的合成:
Figure PCTCN2017093270-appb-000084
探针1
分子转子3(0.199g,0.5mmol)和4-二甲氨基吡啶(0.073g,0.6mmol)于20mL的无水二氯甲烷中溶解,Ar保护条件下缓慢滴加对硝基氯甲酸苯酯(0.121g,0.6mmol)的10mL无水二氯甲烷溶液,滴加完毕,室温搅拌1h,反应完毕,旋转蒸干除去溶剂,残余物溶于10mL无水N,N-二甲基甲酰胺中,加入化合物4-甲胺苯磺酰胺(0.11g,0.60mmol),加入无水三乙胺(0.08mL,0.6mmol),氩气保护条件下室温搅拌30min,反应完毕,旋转蒸干除去溶剂,残余物柱分离,即得纯的化合物0.225g,产率65%。1H-NMR(400MHz,DMSO-d6):δ=8.45(s,1H),8.17(t,1H,J=6.60Hz),8.09(d,1H,J=8.00Hz),8.07(s,1H),7.94(d,1H,J=8.00Hz),7.80(d,1H,J=8.10Hz),7.51(m,1H),7.41(m,3H),7.30(s,2H),6.45(s,1H),4.92(t,1H,J=5.60Hz),4.32(d,1H,J=6.00Hz),3.67(t,2H,J=5.60Hz),3.49(t,2H,J=5.60Hz),3.13(s,3H)。
实施例70
将实施例1-68制备的荧光染料(分子转子)分别溶于二甲基亚砜中,各自制得浓度为1×10-2M的母液,将各母液分别加入甘油和甲醇中,混合均匀,各配制终浓度为1×10-5M的溶液,根据荧光染料不同,依次用各荧光染料最大激发波长在相同条件下检测其荧光发射图谱,结果如表1所示,表明本发明荧光染料具有长波长发射荧光,并且对粘度变化响应灵敏。
表1 各分子转子的发射波长及其在甘油与甲醇溶液的荧光强度之比
Figure PCTCN2017093270-appb-000085
Figure PCTCN2017093270-appb-000086
Figure PCTCN2017093270-appb-000087
实施例71
分子转子1、2、3、22、57、63加入粘度为16.4cp、29.8cp、64.5cp、143.5cp、377.0cp、946.0cp的二乙醇-甘油混合溶液中,配制成终浓度为1×10-5M的溶液,480nm激发,不同粘度条件下荧光发射光谱如图1、4、7、10、13、16所示,分子转子发射波长分别为555nm、590nm、610nm、570nm、559nm、675nm,相同浓度的分子转子在不同粘度条件下荧光强度逐渐增大,说明分子转子荧光强度随环境粘度的增大荧光增强,荧光强度的对数和溶剂粘度的对数关系符合哈夫曼方程,具有很好的线性关系,并且具有较高斜率,如图2、5、8、11、14、17所示,证明分子转子对粘度反应灵敏,并且可以用于未知样品的粘度测试。
实施例72
分子转子1、2、3、22、57、63分别加入二氯甲烷、甲醇中,配制成终浓度为1×10-5M的溶液,然后在25℃条件下分别用480nm、480nm、500nm激发波长激发,检测它们在两种不同极性溶剂中的荧光发射强度,如图3、图6、图9、图12、图15、图18所示,分子转子在溶液中的荧光发射强度微弱,并且,在强极性和强非极性溶剂中荧光强度变化不大,说明本发明的分子转子荧光强度本底荧光微弱,对极性变化反应不灵敏。
实施例73
以Hela细胞为例探讨探针1在碳酸酐酶的荧光监测方面的效果应用。将高表达碳酸酐酶的Hela细胞以及未表达碳酸酐酶Hela-WT细胞(Hela原始细胞,)种植于于14mm玻璃底96孔细胞培养板中,稳定10小时。将探针1加入至培养基中,并使得浓度达到5μM。细胞置于37℃二氧化碳培养箱孵育2小时,使用Leica TPS-8共聚焦显微镜成像检测标记细胞荧光变化。图19Aa中结果显示加入探针1后,Hela-WT细胞中未能检测到相应的荧光信号,说明探针荧光不受细胞内环境影响;而在图19Ba中表达碳酸酐酶蛋白的Hela细胞可以检测到强烈的荧光信号,和Hela-WT细胞相比,荧光信号增强近300倍。说明本发明的探针可以实现特异性标记细胞内碳酸酐酶蛋白,实现荧光特异性点亮,同时,探针荧光不受细胞内环境影响。为证明所增长的荧光是探针1与碳酸酐酶所作用的结果,进一步加入与碳酸酐酶作用更强的依索唑胺,并将它的浓度提高至为10μM,细胞再次置于37℃二氧化碳培养箱孵育1小时,使用Leica TPS-8共聚焦显微镜成像检测标记细胞荧光变化。图19Bb中细胞的荧光强度仅为图19Ba中细胞荧光强度的8%,显示细胞荧光强度剧烈下降,表明荧光的点亮原因在于探针1与碳酸酐酶作用后,分子构象被限制。
该实施例证明本发明的荧光染料适用于与对应的抗体、适配体或淀粉样蛋白等特异性结合,或者通过配体或抑制剂与蛋白标签或酶的键合,并将分子转子导入到酶的内腔等手段和方法,发展出系列荧光激活点亮型探针,用于蛋白、酶或核酸的荧光标记、定量或监测。

Claims (10)

  1. 一种荧光染料,其结构如式(I)所示,
    Figure PCTCN2017093270-appb-100001
    其中:
    D-为X0O-或N(X1)(X2)-,X0、X1、X2各自独立地选自氢、烷基和改性烷基,X1,X2任选相互连接为饱和或不饱和的脂杂环;
    B环为选自芳香环或芳香杂环中的至少一种;
    B环与噻吩环稠合所形成的下式(I-2)结构中,所含的各氢原子任选独立地被选自卤原子、硝基、亲水性基团、烷基和改性烷基的取代基取代,所述取代基任选地相互连接构成饱和或不饱和的脂环或脂杂环;
    Figure PCTCN2017093270-appb-100002
    任选地,所述式(I-2)结构与X1、X2相互连接形成脂杂环;
    R1选自氢、卤原子、硝基、烷基、芳基、杂芳基、亲水性基团或改性烷基;
    R2选自氰基、羧基、酮基、酯基、酰胺基、膦酸基、膦酸酯基、磺酸基、磺酸酯基、砜基、亚砜基、芳基、杂芳基、烷基或改性烷基;
    R3为氰基;
    式(I)中的下式(I-3)结构部分:
    Figure PCTCN2017093270-appb-100003
    任选形成下式(I-3-a)、(I-3-b)环状结构:
    Figure PCTCN2017093270-appb-100004
    其中,Ra、Rb独立地选自氢、烷基和改性烷基,Ra和Rb任选地相互连接形成脂环或脂杂环;
    Rc、Rd独立地选自氢、卤原子、硝基、烷基、芳基、亲水性基团和改性烷基;
    Y1选自-O-、-S-、-(S=O)-和-(NRi)-,其中Ri选自氢、烷基和改性烷基;
    Y2选自=O、=S、=S=O和=NRi,其中Ri选自氢、烷基和改性烷基;
    Y3选自=O、=S、=S=O和=NRi,其中Ri选自氢、烷基和改性烷基;
    或者,Y3为=C(Re)(CN);
    Re选自氰基、羧基、酮基、酯基、酰胺基、膦酸基、膦酸酯基、磺酸基、磺酸酯基、砜基、亚砜基、芳基、杂芳基、烷基或改性烷基;
    当R2或Re为芳基或杂芳基时,环上的氢原子任选独立地被选自卤原子、硝基、亲水性基团、烷基或改性烷基中的取代基取代;任选地,所述取代基相互连接构成饱和或不饱和的脂环或脂杂环;
    其中,
    所述烷基为具有1~10个碳原子的饱和脂肪族直链或支链的烷基;
    所述改性烷基为烷基的任意碳原子被选自卤原子、-O-、-OH、-CO-、-NO2、-CN、
    Figure PCTCN2017093270-appb-100005
    基具有1~50个碳原子,其碳碳单键任选独立地被碳碳双键或碳碳叁键置换;
    所述脂环为4~10元单环或多环脂环;
    所述脂杂环为环上含有选自N、O、S或Si中的至少一种杂原子的4~10元单环或多环脂杂环,所述脂杂环上含有S原子时,其任选为-SO-或-SO2-;所述脂杂环任选被卤原子、硝基、烷基、芳基、亲水性基团和改性烷基取代;
    所述芳基或芳香环为5~10元单环或稠合双环;
    所述杂芳基或芳香杂环为环上含有选自N、O、S或Si中的至少一种杂原子的5~10元单环或稠合双环;
    所述卤原子各自独立地选自F、Cl、Br、I;
    所述亲水性基团为羟基、磺酸基、硫酸基、磷酸基、伯氨基、仲氨基或叔氨基及其取代物;
    所述单环亚环烃基为4~7元亚环烃基;
    所述双环亚环烃基为5~7元双环亚环烃基;
    所述桥联脂杂环为环上含有选自N、O、或S中的至少一种杂原子的5~20元桥联脂杂环。
  2. 根据权利要求1所述的荧光染料,其特征在于,
    所述改性烷基为含有选自-OH、-O-、乙二醇单元、单糖单元、二糖单元、多糖单元、-O-CO-、-NH-CO-、-SO2-O-、-SO-、-SO2-NH-、-S-S-、-CH=CH-、-c≡c-、卤原子、氰基、硝基、磷酸酯基或膦酸酯基中至少一种基团的基团;
    所述脂杂环选自氮杂环丁烷、吡咯烷、哌啶、四氢呋喃、四氢吡喃、吗啉、硫代吗啉;
    所述杂芳环选自噻吩、呋喃、吡咯。
  3. 根据权利要求1所述的荧光染料,其特征在于,X1、X2独立地为任选被1个或多个选自羟基、氰基、卤原子、羧基、季铵基团的基团取代的C1-50直链或支链烷基;或任选被1个或多个选自磺酸基、羧基的基团取代的含1-10个氧原子的C2-50醚链基团;或者,N(X1)(X2)-形成选自下式(I-1-1)~(I-1-4)的任一基团:
    Figure PCTCN2017093270-appb-100006
    其中,Rk为氢或者C1-10烷基。
  4. 根据权利要求1至3任一项所述的荧光染料,其特征在于,所述式(I-2)结构中两个相邻取代基相互连接构成饱和或不饱和的脂环或脂杂环;
    可选地,B环中CH上的H被卤原子、硝基、亲水性基团、烷基或改性烷基取代;
    可选地,B环中含有NH;可选地,所述NH上的H被烷基或改性烷基取代,
    可选地,式(I-2)结构选自下式(I-2-1)~(I-2-17)中的结构:
    Figure PCTCN2017093270-appb-100007
    可选地,式(I-2)结构选自式(I-2-1)、(I-2-3)、(I-2-6)、(I-2-7)、(I-2-9)、(I-2-10)、(I-2-11)、(I-2-14)、(I-2-15)、(I-2-16)或(I-2-17)中的结构。
  5. 根据权利要求1-4任一项所述的荧光染料,其中,式(I-3-a)中Ra、Rb与所连接的碳原子一起形成:
    Figure PCTCN2017093270-appb-100008
    可选地,所述R2和Re独立地为选自以下结构的基团,或者,由以下结构自身或相互之间稠合形成的双环或多环稠芳香环或稠芳香杂环:优选为双环或三环稠芳香环或稠芳香杂环;
    Figure PCTCN2017093270-appb-100009
    可选的,R2或Re的上述结构中CH上的H被卤原子、硝基、亲水性基团、烷基或改性烷基取代;可选地,R2或Re为选自上述结构中的含NH的基团,可选地,所述NH上 的H被烷基或改性烷基取代;
    或者,所述R2和Re独立地为改性烷基:所述改性烷基含有酮基、酯基或酰胺基,并且通过酮基、酯基或酰胺基中的羰基连接到式(I-3)或式(I-3-a)的烯基碳上;
    可选地,所述式(I-3)结构为选自下式(I-3-1)~(I-3-18)中的一种:
    Figure PCTCN2017093270-appb-100010
    可选地,所述式(I-3)结构为选自(I-3-1)、(I-3-2)、(I-3-4)、(I-3-5)、(I-3-7)、(I-3-9)、(I-3-11)、(I-3-12)、(I-3-13)、(I-3-16)、(I-3-17)或(I-3-18)中的一种。
  6. 根据权利要求1-5任一项所述的荧光染料,其特征在于,所述荧光染料选自下式化合物:
    Figure PCTCN2017093270-appb-100011
    Figure PCTCN2017093270-appb-100012
    Figure PCTCN2017093270-appb-100013
    Figure PCTCN2017093270-appb-100014
  7. 制备权利要求1-6任一项所述的荧光染料的方法,其特征在于,包括式(II)化合物与式(III)化合物发生羟醛缩合反应的步骤。
    Figure PCTCN2017093270-appb-100015
  8. 权利要求1-6任一项所述的荧光染料在粘度测试、蛋白荧光标记、核酸荧光标记、蛋白定量或检测、或者核酸定量或检测中的用途。
  9. 一种荧光激活点亮型探针,其特征在于,包括权利要求1-6任一项所述荧光染料。
  10. 权利要求9所述的荧光激活点亮型探针在蛋白荧光标记、核酸荧光标记、蛋白定量或检测、或者核酸定量或检测中的用途。
PCT/CN2017/093270 2016-07-20 2017-07-18 一种荧光染料及其制备方法和用途 WO2018014820A1 (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP17830454.9A EP3489323A4 (en) 2016-07-20 2017-07-18 FLUORESCENT DYE AND PRODUCTION METHOD AND USE THEREOF
JP2019502739A JP7186448B2 (ja) 2016-07-20 2017-07-18 蛍光染料及びその製造方法と使用
US16/318,762 US11365203B2 (en) 2016-07-20 2017-07-18 Fluorescent dye and preparation method and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610573970.XA CN107663384B (zh) 2016-07-20 2016-07-20 一种荧光染料及其制备方法和用途
CN201610573970.X 2016-07-20

Publications (1)

Publication Number Publication Date
WO2018014820A1 true WO2018014820A1 (zh) 2018-01-25

Family

ID=60991947

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/093270 WO2018014820A1 (zh) 2016-07-20 2017-07-18 一种荧光染料及其制备方法和用途

Country Status (5)

Country Link
US (1) US11365203B2 (zh)
EP (1) EP3489323A4 (zh)
JP (1) JP7186448B2 (zh)
CN (1) CN107663384B (zh)
WO (1) WO2018014820A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3798221A4 (en) * 2018-05-18 2022-07-06 Fluorescence Diagnosis (shanghai) Biotech Company Ltd. FLUORESCENT PROBE AND METHOD OF MANUFACTURE AND USE THEREOF

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108300456B (zh) * 2018-01-26 2020-08-18 华南理工大学 一类具有聚集诱导发光性质的荧光化合物在有机胺检测中的应用
CN111592472B (zh) * 2019-04-28 2022-10-21 纳莹(上海)生物科技有限公司 一种荧光染料及其制备方法和用途
CN111593052A (zh) * 2019-04-28 2020-08-28 华东理工大学 一种rna检测与定量的方法
CN110437219A (zh) * 2019-07-09 2019-11-12 济南大学 一种检测粘度和二氧化硫双功能的荧光探针
CN112538482A (zh) * 2019-09-23 2021-03-23 华东理工大学 一种rna检测与定量的方法
CN110702653B (zh) * 2019-10-16 2020-11-24 华中科技大学 一种聚集诱导荧光探针在指纹荧光成像中的应用
CN113501790A (zh) * 2020-03-23 2021-10-15 纳莹(上海)生物科技有限公司 一种荧光染料及其制备方法和用途
CN112876496B (zh) * 2021-03-16 2022-01-28 南京邮电大学 一种有机小分子光学诊疗探针及其制备方法与应用
CN115703771A (zh) * 2021-08-06 2023-02-17 纳莹(上海)生物科技有限公司 一种荧光染料及其制备方法和用途
CN113754603B (zh) * 2021-08-12 2022-04-19 浙江工业大学 一种异恶唑类化合物作为粘度荧光探针的应用
CN114605376A (zh) * 2022-04-21 2022-06-10 济南大学 一种检测半胱氨酸和粘度的双功能荧光探针及其制备

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102146215A (zh) * 2011-01-31 2011-08-10 大连理工大学 一类五甲川菁荧光染料、制备方法及其应用
CN102757659A (zh) * 2012-07-24 2012-10-31 大连理工大学 一类咔唑类半菁荧光染料及其应用
CN105062465A (zh) * 2015-07-31 2015-11-18 山东大学 一类环境敏感型的α1-肾上腺素能受体近红外荧光配体及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3622136A1 (de) * 1986-07-02 1988-01-07 Basf Ag Thienothiophenfarbstoffe
GB0219896D0 (en) 2002-08-27 2002-10-02 Bayer Ag Dihydropyridine derivatives
US8153446B2 (en) 2008-05-23 2012-04-10 Kent State University Fluorogenic compounds converted to fluorophores by photochemical or chemical means and their use in biological systems
EP2291427B1 (en) 2008-06-09 2016-03-30 Solvay USA Inc. Sulfonated polythiophenes comprising fused ring repeat units
ES2307462B1 (es) * 2008-06-30 2009-10-14 Fundacion Universitaria San Pablo Ceu (70%) Derivados de naftofurano y naftotiofeno como agentes antiproliferativos del cancer de pancreas y colon.
WO2010074326A1 (en) 2008-12-25 2010-07-01 Canon Kabushiki Kaisha Probe for a biological specimen and labelling method and screening method using the probe
WO2010141263A1 (en) * 2009-06-05 2010-12-09 Danisco Us Inc. High-throughput molecular rotor viscometry assay
WO2011024774A1 (ja) 2009-08-24 2011-03-03 独立行政法人情報通信研究機構 2次非線形光学化合物及びそれを含む非線形光学素子
KR101985184B1 (ko) * 2011-01-28 2019-06-03 주식회사 동진쎄미켐 신규한 유기염료 및 이의 제조방법
WO2012103678A1 (zh) 2011-01-31 2012-08-09 大连理工大学 一类五甲川菁荧光染料、制备方法及其应用
US8841409B2 (en) 2012-03-22 2014-09-23 Polyera Corporation Conjugated polymers and their use in optoelectronic devices
JP2013194039A (ja) 2012-03-22 2013-09-30 Nippon Shokubai Co Ltd ホウ素含有化合物及びその製造方法
SG11201502289RA (en) 2012-09-26 2015-04-29 Agency Science Tech & Res Fluorescent molecular rotors
JPWO2014103831A1 (ja) * 2012-12-28 2017-01-12 株式会社Adeka 担持体及び光電変換素子
KR101718867B1 (ko) * 2014-06-02 2017-03-22 한국과학기술연구원 생체적합성 형광 나노입자 및 이의 용도
CN105566942A (zh) * 2015-10-13 2016-05-11 华东理工大学 一种长发射波长荧光染料的制备方法
CN107641121B (zh) * 2016-07-20 2021-02-19 上海高驰资产管理有限公司 一种荧光探针及其制备方法和用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102146215A (zh) * 2011-01-31 2011-08-10 大连理工大学 一类五甲川菁荧光染料、制备方法及其应用
CN102757659A (zh) * 2012-07-24 2012-10-31 大连理工大学 一类咔唑类半菁荧光染料及其应用
CN105062465A (zh) * 2015-07-31 2015-11-18 山东大学 一类环境敏感型的α1-肾上腺素能受体近红外荧光配体及其应用

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BLENKLE, M. ET AL.: "Chalcogens as electron donors for selected nonlinear optic phores", J. CHEM. SOC., PERKIN TRANS, vol. 2, 31 December 1996 (1996-12-31), pages 1377 - 1384, XP055588768 *
ECHEVERRY, C.A. ET AL.: "New organic dyes with high IPCE values containing two triphenylamine units as co-donors for efficient dye-sensitized solar cells", RSC ADVANCES, vol. 5, 31 December 2015 (2015-12-31), pages 60823 - 60830, XP055454251 *
GAO, PENG ET AL.: "Fine-tuning the Electronic Structure of Organic Dyes for Dye-Sensitized Solar Cells", ORGANIC LETTERS, vol. 14, no. 17, 10 August 2012 (2012-08-10), pages 4330 - 4333, XP055454257 *
GAO, YURONG ET AL.: "Synthesis and photoelectric properties of an organic dye containing benzo[l, 2-b:4, 5-b'] dithiophene for dye-sensitized solar cells", CHINESE CHEMICAL LETTERS, vol. 24, 4 February 2013 (2013-02-04), pages 149 - 152, XP029003679 *
HAO, XIAOLI ET AL.: "Organic Dyes Incorporating the Benzo [1, 2-b:4, 5-b0] dithiophene Moiety for Efficient Dye-Sensitized Solar Cells", ORGANIC LETTERS, vol. 13, no. 20, 29 September 2011 (2011-09-29), pages 5424 - 5427, XP055454262 *
LI, WEI ET AL.: "What Makes Hydroxamate a Promising Anchoring Group in Dye-Sensitized Solar Cells? Insights from Theoretical Investigation", THE JOURNAL OF PHYSICAL CHEMISTRY LETTERS, vol. 5, 3 November 2014 (2014-11-03), pages 3992 - 3999, XP055588759 *
PAL, S.K. ET AL.: "Synthesis, characterization and laser flash photolysis studies of some naphthothiophenes bearing electron donor and acceptor functional groups", JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY A: CHEMISTRY, vol. 174, 4 May 2005 (2005-05-04), pages 138 - 148, XP025301299, DOI: doi:10.1016/j.jphotochem.2005.03.005 *
See also references of EP3489323A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3798221A4 (en) * 2018-05-18 2022-07-06 Fluorescence Diagnosis (shanghai) Biotech Company Ltd. FLUORESCENT PROBE AND METHOD OF MANUFACTURE AND USE THEREOF

Also Published As

Publication number Publication date
US11365203B2 (en) 2022-06-21
JP7186448B2 (ja) 2022-12-09
JP2019527279A (ja) 2019-09-26
EP3489323A1 (en) 2019-05-29
US20190241584A1 (en) 2019-08-08
EP3489323A4 (en) 2020-05-06
CN107663384B (zh) 2020-05-12
CN107663384A (zh) 2018-02-06

Similar Documents

Publication Publication Date Title
WO2018014820A1 (zh) 一种荧光染料及其制备方法和用途
WO2018014821A1 (zh) 一种荧光探针及其制备方法和用途
EP1866387B1 (en) Polar dyes
WO2019062876A1 (zh) 一种荧光探针及其制备方法和用途
EP1140856B1 (en) Fluorescent dyes for solid phase and solution phase screening
WO2019218876A1 (zh) 一种荧光探针及其制备方法和用途
WO2020221217A1 (zh) 一种荧光染料及其制备方法和用途
Bora et al. Diazaoxatriangulenium: synthesis of reactive derivatives and conjugation to bovine serum albumin
JP4921641B2 (ja) 新規のカルボピロニン蛍光色素
Dell’Acqua et al. MediaChrom: discovering a class of pyrimidoindolone-based polarity-sensitive dyes
Wang et al. Precise design and synthesis of an AIE fluorophore with near-infrared emission for cellular bioimaging
ES2621507T3 (es) Nuevos complejos a base de iridio para EQL
Bordeau et al. meta-Substituted triphenylamines as new dyes displaying exceptionally large Stokes shifts
JP5319130B2 (ja) ケイ光ソルバトクロミック色素及びその使用法
CN112174988B (zh) 三聚稀土铽配合物及其制备方法
WO2023011656A1 (zh) 一种荧光染料及其制备方法和用途
CN112812584A (zh) 一种含氮杂环丁烷螺环结构的荧光染料及其制备方法和应用
CN116535378A (zh) 罗丹明类荧光染料及其应用
CN117088881A (zh) 氮杂双环戊萘类荧光分子探针及制备和应用
CN118005601A (zh) 一种具有聚集诱导发光性能的化合物及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17830454

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019502739

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2017830454

Country of ref document: EP

Effective date: 20190220